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 In recent years, the fields of regenerative medicine and developmental biology have been 
revolutionized by the ability to reprogram adult somatic cells back to a pluripotent state, producing 
induced pluripotent stem cells (iPSCs) through the induction of the reprogramming factors OCT4, SOX2, 
KLF4 and c-MYC (OSKM). The promise of this technique has been somewhat limited by the low 
efficiency and long duration of the process which produces heterogeneous mixtures of cells in culture, 
many of which fail to fully reprogram over a 3-4 week period. Research in recent years has focused on the 
underlying mechanisms of reprogramming and identifying rate-limiting steps in the process. Most studies 
to date utilize bulk measurements of cells undergoing reprogramming however, these techniques cannot 
measure the changes occurring in rare cells that will become iPSCs and are inherently biased towards 
unsuccessful reprogramming events. Here we apply single cell technologies to measure the dynamics of 
mRNA and protein expression and develop mathematical models to precisely describe these behaviors. 
We find that productively reprogramming cells activate genes in an ordered, probabilistic fashion but do 
so independently of one another, lacking hallmarks of gene regulatory network activity. Some genes, 
despite their expression as mRNAs, are not immediately translated into protein, identifying post-
transcriptional mechanisms as a potential rate limiting step. In contrast, cells moving along an alternate 
trajectory away from fibroblast but not towards iPSC, fail to activate pluripotency genes and do not 
express the full complement of OSKM. This is due to premature inactivation of the individual factors, 
causing cells to drop off the productive trajectory and fail to reprogram. Performing these analyses under 
two different delivery methods of OSKM and in two cell types reveals that while the timing of gene 
activation varies between conditions, the probabilistic order of gene activation is conserved, suggesting a 
common reprogramming trajectory. Taken together these findings represent the first descriptions of  
 Frederick Kolling IV – University of Connecticut, 2015 
mRNA and protein expression dynamics in single, human cells undergoing reprogramming. We also 
provide a robust mathematical framework for identifying rate-limiting steps in the process and dissecting 
the mechanism of action of treatments known to enhance the efficiency of reprogramming. 
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Chapter 1 Introduction 
1.1 Project Context and Significance 
A pluripotent, embryonic stem cell (ESC) cell is defined by its ability to differentiate into all 
three embryonic germ layers (endoderm, mesoderm and ectoderm) and can thus contribute to all cell 
types of an adult organism1. In 2005 Takahashi et al demonstrated that overexpression of the transcription 
factors OCT4, SOX2, KLF4 and c-MYC (OSKM) could revert differentiated somatic cells to a 
pluripotent state 2. This process of somatic cell reprogramming generates induced Pluripotent Stem Cells 
(iPSCs), which promise to revolutionize the field of regenerative medicine. While this technique was 
developed nearly a decade ago, many barriers still exist to the efficient and reproducible derivation of 
iPSCs by this method 3–5. At the time this project was initiated much of the focus in the reprogramming 
field was on developing different methods to improve the efficiency of the process by manipulating the 
delivery method of OSKM and introducing new factors or small molecules to the cocktail 6,7.  These 
efforts yielded small increases in efficiency and provided some insight into the barriers to successful 
reprogramming, however little was known about the molecular changes occurring during the transition 
from the somatic to pluripotent state. Early efforts aimed at studying the process itself relied on bulk 
measurements of cells undergoing reprogramming and were performed primarily in mouse 8–11. Because 
reprogramming is temporally asynchronous and produces considerable cellular heterogeneity 11–14, these 
approaches are not optimal for understanding this process in detail. In addition, many variables contribute 
to the overall rate and efficiency of reprogramming including the species and cell type of the starting 
population, as well as the method used to initiate the process.  
 For these reasons, the goal of this project is to use single cell genomic and proteomic 
technologies to profile individual cells at the transcript and protein level as they are driven from a somatic 
to a pluripotent state in human cells. Since the initiation of the project six years ago, the field has 
advanced at a dizzying pace and other single-cell resolution studies of the process have been reported. 
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However, this work represents the first single cell analysis of mRNA and protein expression in human 
reprogramming and the first to compare the dynamics of the process under different reprogramming 
conditions. This methodology provides novel insights into how human cells acquire pluripotent 
characteristics, a necessary step for the therapeutic implementation of the technique. In addition, the 
statistical methods utilized herein contribute to the nascent field of single-cell data analysis and provide a 
framework for deconstructing complex biological populations that can be extended to a variety of 
systems.   
1.2 The Epigenetic Landscape 
During normal development, pluripotent cells with the ability to generate all tissues of the 
organism progressively lose their developmental potential as they differentiate into increasingly 
specialized cell types 10,15–18. Known as canalization, this process was first articulated in 1948 by Conrad 
Waddington rapidly becoming a dogma of developmental biology. He likened the developmental 
potential of a cell to a ball rolling down a hill. Just as a ball loses potential energy as it reaches the base of 
the hill, so too does a cell lose developmental potential as it differentiates into increasingly specialized 
cell types. This epigenetic landscape as he called it, becomes more restrictive as development proceeds, 
inactivating regions of the genome and thus canalizing the developmental potential of the cell. It is this 
epigenetic restriction that produces stable cell types and prevents their spontaneous reversion to a more 
primitive developmental state. Conversely, reprograming to pluripotency represents a reversal of 
developmental potential, akin to rolling the ball back up the hill. This process requires a strong external 
force to perturb a cell from its stable somatic state followed by a suite of molecular changes including 
resetting of the epigenetic landscape that must occur en route to pluripotency 4,8,19,20.  
1.3 Methods of Reprogramming 
Reprogramming was first demonstrated using Somatic Cell Nuclear Transfer (SCNT) to generate 
pluripotent cells by transferring the nucleus of a differentiated cell type into an enucleated oocyte 21. 
SCNT remains the most rapid and efficient method of generating pluripotent cells in vitro and has been 
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widely used to clone animals from a variety of species 22–26. This method was recently demonstrated to 
work in human cells 27 however, it remains highly controversial and requires an abundance of oocyte 
donors in order to be feasible for therapeutic purposes.  
In 2005, Takahashi et al used retroviruses to overexpress the transcription factors OCT4, SOX2, 
KLF4 and c-MYC (OSKM) to reprogram skin fibroblasts to pluripotency at an efficiency of 0.01% over a 
period of 30 days 2,28. This finding was heralded as a boon for regenerative medicine, promising to 
provide patient-derived stem cells for therapeutic purposes while avoiding the ethical concerns of SCNT. 
Because retroviruses containing the 4 factors integrate randomly and may induce unintended alterations to 
the host genome, they are not ideal for use in therapeutic applications 29,30. To address this issue, methods 
have been developed to reprogram cells using floxed OSKM cassettes or piggy-bac vectors to generate 
“footprint-free” iPSCs 31–34, as well as non-integrating methods such as episomal vectors or mini-circle 
constructs 31,35–37. Cells have also been reprogrammed by DNA-free approaches including mRNA/miRNA 
transfection, protein transduction and recently, small molecule cocktails 38–42. In addition to altering the 
delivery method of OSKM, other factor combinations have also been used to successfully reprogram 
cells. In particular, the Thompson cocktail of OCT4, SOX2, NANOG and LIN28 has been particularly 
effective and has been shown to act synergistically with OSKM, suggesting these factors promote 
reprogramming by distinct pathways 6. 
1.4 Interrogating the Reprogramming Process 
Great strides have been made in recent years to uncover the molecular changes occurring during 
reprogramming however, our ability to interpret and synthesize these results into meaningful models is 
complicated by three key features of the process. First, the low efficiency of reprogramming results in 
1:1,000 – 1:10,000 cells being successfully reprogrammed. Second, infection with OSKM produces 
considerable cellular heterogeneity as evidenced by the variety of stable, partially reprogrammed 
intermediates that can be isolated at various stages of the process and the transcriptional and epigenetic 
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variation observed in fully reprogrammed iPSCs 2,9,43–48. Lastly, reprogramming is temporally 
asynchronous with cells responding to OSKM and progressing towards pluripotency at different rates 11.  
The majority of the studies to date rely on the analysis of bulk populations of reprogramming 
cells and thus are inherently biased towards measuring events that do not lead to pluripotency. In addition 
the asynchrony and heterogeneity of the process results in bulk expression profiles that reflect an 
averaging of a continuum of cell states, rather than a discrete population. Despite these complications, 
population-level measurements have shed light on the ensemble protein and mRNA expression changes 
during reprogramming and provide insight into the major molecular changes required to achieve 
pluripotency. Understanding the events occurring in the minority of cells that become iPSCs however, 
requires techniques with resolution at the single-cell level.  
The first single-cell technology used to interrogate the reprogramming process was time-lapse 
microscopy, whereby cells infected with OSKM were recorded over time and monitored for changes in 
cell morphology, cell cycle rate and the expression of reporter genes linked to successful reprogramming 
49. In particular, Nanog-GFP and Oct4-GFP reporters have been commonly used to monitor the 
endogenous activation of these key pluripotency loci, events that have been shown to occur late in the 
process 11,12,50,51. Retroactive tracing of these reporter-positive populations back to their initial infection 
with OSKM has revealed a stepwise progression of cells through the reprogramming process, 
characterized by an early increase in cell-cycle rate and decrease in cell size, followed by a mesenchymal 
to epithelial transition and lastly, the activation of the GFP reporter construct 51–55. The fact that these 
events occur in a reproducible order suggests that reprogramming is an ordered process, however the 
molecular resolution of this technique is limited and cannot interrogate mRNA and protein-level changes 
with appreciable throughput.  
The advent of single-cell genomics and proteomics solutions has allowed genome/proteome-wide 
profiling of individual cells undergoing reprogramming. While this thesis project was being completed, 
single-cell mRNA profiling was performed in both mouse and human cells utilizing FACS to enrich for 
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individual productive reprogramming events followed by qPCR or mRNA-seq 56,57. Recently, single cell 
proteomics methodologies such as CyTOF, which allows the simultaneous analysis of up to 40 proteins in 
1 X 105 – 1 X 106 individual cells has been applied to mouse reprogramming, adding an additional level 
of resolution to our understanding of the process 58,59. The specific findings and models derived from 
these studies are elaborated below.  
1.5 Molecular Dynamics during Reprogramming to Pluripotency 
Reprogramming to pluripotency requires an exquisite coordination of molecular/cellular events to 
revert a “terminally” differentiated somatic cell back to an embryonic pluripotent state, a feat equivalent 
to developmental time-travel. These alterations in cell state encompass every biological process 
imaginable, from mRNA, protein, miRNA and non-coding RNA expression, to epigenetics, metabolism 
and morphology. What follows is an attempt to summarize the vast array of knowledge accumulated to 
date about these processes but which is likely to evolve rapidly as the field continues to progress at an 
astonishing rate.  
1.5.1 Epigenetics 
Perhaps the greatest rate-limiting step to successful reprogramming is the resetting of the 
epigenetic landscape from a somatic to a pluripotent state. This includes DNA methylation and histone 
modifications which can control the expression of individual loci and thus, most if not all molecular 
changes occurring during reprogramming (mRNA, miRNA, lncRNA, protein etc.) first require a change 
in epigenetic state.  These changes are not merely a consequence of reprogramming, but can directly 
influence the course of reprogramming as well. This is evidenced by the effects of small molecule 
chromatin modifiers and altered expression of chromatin-modifying enzymes on the efficiency of the 
process. In general, molecules/factors that promote open chromatin structure such as the HDAC inhibitors 
valproic acid (VPA) and trichostatin A (TSA) or over-expression of the trithorax subunit WDR5 
(involved in H3K4me3) improve efficiency 60–62, while interventions that reinforce repressive chromatin 
like knockdown of the H3K9 demethylase LSD1, reduce efficiency 63,64. In addition to these generalized 
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observations, much is known about the specific chromatin state changes taking place during 
reprogramming as well.  
Almost as soon as reprogramming factor expression is initiated, a plethora of epigenetic 
modifying enzymes are upregulated, including histone methyltransferases, histone 
deacetylases/acetyltransferases and nucleosome remodeling complexes65. Early in reprogramming, 
somatic genes that will eventually become silenced lose the activating H3K4me3 mark and gradually 
acquire repressive H3K27me3 8,66.  The converse happens at loci activated during the process, particularly 
genes that are peripheral to the “core” pluripotency network, where H3K27me3 is lost in favor of 
H3K4me3. Often, these changes occur first in the enhancer regions, followed by changes at the promotor 
of the corresponding loci 67. Later in reprogramming (around day 10 in mouse), H3K9me3 and DNA 
methylation changes occur. These modifications are typically associated with long-term silencing of 
genes and are commonly found among the core pluripotency factors including OCT4, SOX2, NANOG 
and others 68,69.  While it is unclear how DNA methylation is removed during reprogramming, it is 
thought to occur through both active and passive means; passively through the dilution of the 
modification by DNA replication without maintenance of the methylation mark and actively through the 
expression of the Tet and Aid demethylation enzymes 70,71. Loss of DNA methylation at core pluripotency 
loci by either means is a key late-step in reprogramming, as evidenced by the conversion of stable, 
partially reprogrammed cells to pluripotency after treatment with the DNA methylation inhibitor 5-aza-
cytidine 9,61. In conjunction with the aforementioned epigenetic changes, a subset of loci, mostly 
transcription factors involved in development, acquire a bivalent chromatin state characterized by co-
occupancy of active H3K4me3 and repressive H3K27me3. This occurs gradually over the course of 
reprogramming and the dynamics of this change is poorly understood 72,73. 
1.5.2 Transcription  
 Transcriptional changes occurring early in reprogramming are governed by the binding of the 
OSKM transcription factors to DNA as dictated by the epigenetic landscape. An early wave of gene 
7 
 
induction is associated with promoter regions decorated with the activating histone mark H3K4me3 and 
the binding of c-MYC and KLF4 67,74. This includes a set of “early pluripotency” genes as well as loci 
associated with apoptosis. Indeed, apoptosis is a common end-point for many reprogramming cells and 
knockdown of p53 by shRNA has been used to increase reprogramming efficiency 31,75,76. Simultaneously, 
late pluripotency loci that possess repressive epigenetic marks such as H3K27me3 and DNA methylation 
in somatic cells, are bound by a combination of O, S, K and/or M at their distal enhancer regions but 
remain transcriptionally inactive at this stage. During the second wave of transcriptional activity a 
concomitant loss of H3K27me3 and DNA methylation and gain of H3K4me3 occurs at genes that will 
become active in the pluripotent state (i.e. late pluripotency genes). At this stage, the expression of 
pluripotency loci is governed by combinations of transcription factors similar but not identical to those 
observed in true hESCs/iPSCs.   
 While the above primarily refers to changes in mRNA expression, miRNA and lncRNA 
expression have also been measured during the course of reprogramming 40,41,77–80. The expression of 
miRNAs exhibits a biphasic pattern similar to that of mRNA expression, with miRNAs targeting 
fibroblast genes induced early and those targeting pluripotency genes down-regulated late in the process. 
This results in the expected inverse correlation between the expression of miRNAs and their 
corresponding mRNA targets. For example, miR-294 is upregulated early in reprogramming and its target 
TGFBR2 is subsequently downregulated as cells reprogram39,78,81. The opposite is true for the let-7 
miRNA which is turned off late in reprogramming, allowing the pluripotency loci LIN28 and SALL4 to 
be activated in the iPSC state82. Similarly, the expression of lncRNAs have recently been shown to shift 
from a fibroblast to pluripotent expression profile 83. lncRNAs recruit epigenetic modifying complexes to 
target loci and thus play an important role in establishing the epigenetic landscape and stabilizing cellular 
identity. Taken together, the dynamics of mRNA, miRNA and lncRNA expression demonstrate the 
concerted transcriptional changes that must occur as cells transition to a pluripotent state, each of which 
represents a potential barrier to successful reprogramming.  
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1.5.3 Protein Expression 
 In bulk samples subjected to LC/MS-MS, protein expression dynamics reflect what is seen at the 
mRNA level, with an early wave of activation associated with MYC target loci and a late wave of 
pluripotency gene activation 84,85. Interestingly, by comparing these data with bulk mRNA-seq 
measurements collected in parallel, these authors also find that genes involved in cell adhesion, 
androgen/oestrogen signaling and mitochondrial function have a lower correlation at the protein 
compared with the mRNA level. These findings were extended by Hansson et. al. who demonstrated 
mRNA and protein expression exhibit greater correlation early in reprogramming and that this 
relationship deteriorates later in the process. Together, this suggests that post-transcriptional regulation of 
protein expression may be a rate limiting step in the reprogramming process, however it is unclear if this 
phenomenon occurs in the few cells undergoing productive reprogramming which would require single-
cell resolution to establish definitively.  
Recently, mass cytometry (CyTOF) has emerged as a technology to profile protein expression in 
individual cells using a combination of flow cytometry and mass spectrometry which can measure ~40 
proteins in hundreds of thousands of individual cells86. This technique was recently used to profile mouse 
fibroblasts undergoing reprogramming for a panel of 34 proteins58,59. While these studies did not report 
waves of expression as indicated by bulk analysis, they did identify apparent intermediate states on the 
route to pluripotency. This includes an early OCT4highKLF4high population that later activates CD73 and 
CD104 and finally EpCAM before acquiring an iPSC-like profile. This late activation of EpCAM, a 
marker of MET is in contrast to previous reports at the mRNA level that MET is an early event in the 
process. Again, the discordance between mRNA and protein expression suggest post-transcriptional 
regulation may play an important role in the reprogramming process. In addition to the above-mentioned 
trajectory, these authors also identify a subset of reprogramming cells that exit the cell cycle (as 
evidenced by low Ki67 expression) and altogether fail to productively reprogram. Most importantly, these 
studies have identified a unique intermediate CD73+, CD49d+, CD200+ population of cells, of which 12% 
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become iPSCs. This represents the greatest enrichment for productive reprogramming intermediates to 
date and demonstrates the power of CyTOF to identify useful biomarkers in highly heterogeneous 
populations of cells. Furthermore, CyTOF can interrogate post transcriptional modifications such as 
phosphorylation and methylation of histones and other proteins, permitting single cell analysis of entirely 
new levels of cellular activity such as epigenetics and the kineome. 
1.5.4  Cell Cycle 
Human fibroblasts (and many other somatic cell types) exhibit doubling times on the order of 24-
36hrs whereas ESCs double once every 16-18hrs53,87–89. This represents a challenge for reprogramming 
cells to increase their progression through the cell cycle and proliferate more rapidly. It is thought that a 
major role of c-MYC in the OSKM cocktail is to increase proliferation of cells and while reprogramming 
can succeed in its absence, the efficiency is ~100-fold lower 32,74,90. Not only is an increase in cell cycle 
progression critical for the maintenance of pluripotency, it is also thought to facilitate changes in the 
epigenetic landscape 11,91; the replication of the genome represents an opportunity to dilute somatic 
epigenetic modifications while marks associated with pluripotency are established on the newly 
synthesized DNA. This is corroborated by a report from Hanna et al., whose modeling of the 
reprogramming process showed that the number of cell divisions is a better predictor of successful 
reprogramming than days post OSKM induction11. 
1.5.5 Mesenchymal to Epithelial Transition 
 Many cell types used for reprogramming including fibroblasts are mesenchymal in nature, 
making limited cell-to-cell contacts and producing extra cellular matrix components to facilitate adhesion 
to and mobility across surfaces. These cells also express characteristic mesenchymal genes including N-
Cadherin, Vimentin, Fibronectin, Snai2 and Twist, the maintenance of which is dependent on TGFB 
signaling54,92,93. In contrast, embryonic stem cells form an epithelium with tight cell-to-cell junctions and 
form colonies in culture with basal-apical polarity, an activity primarily coordinated by the expression of 
E-Cadherin and EpCAM94,95. Reprogramming cells must undergo a mesenchymal to epithelial transition 
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(EMT), a critical step in the conversion to pluripotency, but there are conflicting reports as to whether this 
is an early or late event in the process55,58,96.  
1.5.6 Inactivation of OSKM Viruses 
 For reprogramming methods that rely on viral delivery of OSKM, inactivation of the four factors 
is a critical late step in forming iPSCs4,97. The persistence of OSKM expression is associated with the 
generation of non-iPSC, self-renewing cell types in reprogramming cultures as well as aberrant 
differentiation of iPSCs into target cell types33,98–100.  This is due to the sensitivity of ESCs and iPSCs to 
transcription factor dosage which control the balance between pluripotency and differentiation101–103. For 
example, persistent OCT4 expression prevents the differentiation of iPSCs, while as little as 2.5-fold 
overexpression of SOX2 downregulates pluripotency targets and promotes differentiation to neuronal and 
mesodermal lineages104–106. While the importance of inactivating OSKM in iPSCs is well understood, the 
mechanisms by which this occurs are not. It has been found that silenced retroviral elements in ESCs are 
associated with H3K9me3 and DNA methylation and binding of the MeCP2 and HP1 proteins in the viral 
LTRs. However, none of the known mediators of these modifications are specifically expressed in cell 
types where silencing occurs and thus the factors involved in this process have yet to be identified97,107–109.  
1.6 Models of the Reprogramming Process 
Through the extensive molecular data generated in recent years, a model of the reprogramming 
process has emerged. The variety of datasets (mRNA vs protein, single-cell vs bulk, etc.) somewhat 
complicates a unified model, however several common themes have been observed.  In 2013, Buganim et 
al proposed a two-phased model of reprogramming following single cell mRNA analysis in the mouse 
system. They observed that cells responding to OSKM infection initially transition through a “stochastic 
phase,” whereby gene expression patterns appear random and uncoordinated. This is followed by a 
“deterministic phase” with cells activating key pluripotency loci in a stepwise, hierarchical fashion56,110. 
While the deterministic phase is thought to occur rapidly as cells become locked into a pluripotent fate, 
the stochastic phase is protracted and probabilistic, resulting in the asynchrony or “variable latency” that 
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is characteristic of the process. This is concordant with the observations that the binding of the OSKM 
factors early in reprogramming (48hrs post-infection) is dictated by the epigenetic state of the target loci 
and that changes in the epigenetic state is required for factor binding to some loci, in particular 
pluripotency genes with repressive chromatin states67. Remodeling of the epigenetic landscape is 
facilitated by DNA replication and cell division and thus increased in cell cycle have been shown to 
improve reprogramming efficiency. Consistent with this notion, factors that increase cell proliferation and 
promote permissive chromatin states (ie histone acetylation) also improve the efficiency of 
reprogramming111.   
The deterministic phase was identified by comparing the expression profiles of single-cells late in 
the reprogramming process that had not activated an Oct4-GFP reporter, with Oct4-GFP+ reprogramming 
cells. Bayesian analysis of these populations revealed a hierarchy of pluripotency gene activation initiated 
by the expression of Sox2. Successful reprogramming, albeit at a lower efficiency, was observed by 
overexpression of downstream members in this cascade in the absence of Sox2, further corroborating 
these findings.  
Taken together, this model implicates the stochastic phase as the major rate limiting step in 
reprogramming and provides a target for improving the rate and efficiency of the process. In contrast, 
dissection of the hierarchical phase is likely to provide informative biomarkers that can be used to identify 
successful reprogramming events. This model, while supported by data from human reprogramming 
experiments is largely comprised of studies performed in mouse and it is unclear how these findings 
translate between the two species.  
1.7 Mouse vs Human 
 The therapeutic potential of reprogramming is dependent on our ability to understand and 
optimize the technique in human cells. Despite this fact, the overwhelming majority of research into the 
mechanisms and dynamics of the process comes from studies in mouse due to the abundance of genetic 
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tools available to manipulate these cells and the increased speed of reprogramming in this system112–114. 
Reprogramming in mouse occurs in as little as 10 days, compared with 30 days in human cells and the 
efficiency can be up to 20-fold higher in mouse91. In addition, many studies of reprogramming in mouse 
take advantage of secondary reprogramming systems whereby mouse fibroblasts are infected with a 
doxycycline-inducible OSKM construct, reprogrammed to iPSCs and subsequently re-differentiated into 
fibroblasts. Addition of doxycycline to these cultures allows for a more homogeneous reprogramming 
process and facilitates molecular dissection of the events leading to pluripotency. It is unclear however, 
whether the prior reprogramming of these cells faithfully represents the process as it occurs in primary 
fibroblasts. Thus, much of what we know about the molecular underpinnings of reprogramming come 
from artificial mouse systems and it is unclear how these finding translate to human cells. While it is 
expected that the cellular processes involved will be consistent between species, the particular genes 
implicated in these processes may be different. Indeed, the wiring of the gene regulatory networks 
governing early development are quite varied between the two species115. Nonetheless, much of the 
information to date comes from mouse reprogramming, illustrating the need for similarly detailed studies 
to be performed in human cells. 
1.8 Scope of the Thesis 
The primary goal of this thesis is to profile the transcript and protein dynamics in human cells 
undergoing reprogramming by OSKM at single-cell resolution and to model progression of cells through 
the stochastic phase. After establishing a baseline model, this analysis is performed under two delivery 
methods of the OSKM virus (monocistronic and polycistronic) and in two different cell types (BJ and 
MRC-5 fibroblasts) to better understand how differences in reprogramming conditions impact the 
acquisition of pluripotency.  
Because much of our current knowledge of reprogramming comes from transgenic mouse 
systems and a variety of reprogramming methods, it remains to be seen how these findings translate to the 
human reprogramming system and whether the method of reprogramming has an impact on the process. 
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By examining both mRNA expression dynamics under different reprogramming conditions as well as 
protein expression, this work provides a unified model of the reprogramming process that is directly 
relevant to the therapeutic application of the technique. In addition, the statistical models developed 
herein provide powerful tools for the field of single-cell analysis to dissect and interrogate heterogeneous 
mixtures of cells.  
Chapter 2 Single Cell Analysis and Modeling of Monocistronic Reprogramming 
by OSKM 
 
This work was published in PLOS ONE in 2014 
2.1 Introduction 
Methods of reprograming somatic cells to a pluripotent state (iPSC) have enabled the 
direct modeling of human disease and ultimately promise to revolutionize regenerative medicine 
5,116. While iPSCs can be consistently generated through viral infection with the Yamanaka 
Factors OCT4, SOX2, KLF4, and c-MYC (OSKM) 2, infected cells rapidly become 
heterogeneous with significant differences in transcriptional and epigenetic profiles, as well as 
developmental potential 14,46,117–119. This heterogeneity, the low efficiency of iPSC generation 
(0.1-0.01%) and the fact that many iPSC lines display karyotypic and phenotypic abnormalities 
44,120,121 has hindered the production of iPSCs that can be used safely and reliably in a clinical 
setting. A thorough mechanistic understanding of the reprogramming process is critical to 
overcoming these barriers to the clinical use of iPSC. 
In the past several years, ChIP-seq and RNA-Seq experiments have revealed ensemble 
gene expression and epigenetic changes that occur during reprogramming by OSKM, and have 
greatly enhanced our understanding of the process 5,10,50,66,122. These studies require the use of 
populations of cells comprised of heterogeneous mixtures undergoing reprogramming (0.01-
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0.1% of which will become iPSC) or stable, partially reprogrammed self-renewing lines arrested 
in a partially reprogrammed state, unlikely to ever become iPSCs without additional 
manipulation 14,117–119. Because these techniques rely on either the ensemble properties of mixed 
populations, or upon the analysis of cell lines arrested at partially reprogrammed states that may 
not be representative of normal intermediate steps in a functional reprogramming process, they 
have limited ability to reveal the changes that appear to be essential to successful 
reprogramming. 
Longitudinal single-cell imaging studies provide a powerful complement to ensemble, 
population level analyses. Live imaging studies have identified a number of key morphological 
and cell cycle related changes that occur during reprogramming to iPSC 55,123. These 
observations suggest that an ordered set of phenotypic changes precede acquisition of the fully 
pluripotent state 10. However, these studies are necessarily limited in their molecular-genetic 
resolution, and they provide little insight to the transcriptional changes accompanying key 
morphological and developmental transitions in the reprogramming process. 
Recently, a single-cell transcriptional analysis of reprogramming of mouse fibroblasts by 
OSKM revealed that reprogramming proceeds in two major phases: an early stochastic phase 
followed by a rapid “hierarchical” phase 110. While the latter phase appears deterministic and is 
characterized by the coordinated expression of pluripotency genes in an ordered fashion, the 
early phase exhibits apparently random gene expression patterns that persist through the majority 
of the process 110,124. This conclusion is further supported by two key pieces of evidence from 
other studies: 1) transgenic OSKM activity is required for the majority of the reprogramming 
process, indicating that most of this process is not governed by the concerted action of the 
endogenous pluripotency gene regulatory network (GRN) 51,52,123; and 2) a mechanistically 
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undescribed period of variable ‘latency’ of cells in the stochastic phase results in significant 
temporal variability in the appearance of fully reprogrammed iPSC colonies 11. Some insight to 
pluripotency gene activation during the stochastic phase was provided by a recent study in mouse 
fibroblasts that describes the ‘gradual activation of pluripotency genes’ between the initial 
response to OSKM induction and the activation and stabilization of the pluripotency GRN 8. 
Together, these findings suggest that the stochastic phase is a major rate-limiting step in the 
reprogramming process, but provide little mechanistic insight into the molecular underpinnings 
of these events. In addition, it has not yet been determined how these findings translate to the 
reprogramming of human cells, which will be required prior to clinical application of iPSCs. 
Several studies have attributed the protracted stochastic phase to the requirement for 
extensive chromatin remodeling during reprogramming 21,125. These changes involve the 
complex coordination of factors to deposit and remove histone modifications and DNA 
methylation at specific loci to achieve a pluripotent epigenetic state. The need to reset the 
epigenetic landscape appears to delay the coordinated activation of the pluripotency GRN and is 
likely to be a major barrier to rapid and efficient reprogramming. Indeed, it has been shown that 
OSKM binding in the early stages of reprogramming is greatly impeded by the presence of 
repressive chromatin, and initial binding is largely restricted to existing open chromatin domains 
5,50,66,67,69. Subsequent remodeling of somatic cell chromatin clearly occurs, but the order and 
mechanism of remodeling events during the stochastic phase is not fully understood. Accurate 
mapping of gene expression dynamics during the stochastic phase can provide a framework for 
the molecular dissection of these rate-limiting events in reprogramming. 
In this study we perform single-cell transcript analysis of MRC-5 human lung fibroblasts 
undergoing reprogramming by OSKM and find that cells appear to follow two trajectories: one 
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toward an ESC-like state (the “productive” trajectory) and the other away from both ESC and 
fibroblasts (the “alternative” trajectory). These trajectories can be differentiated by the concerted 
consolidation of expression of a suite of chromatin modifiers in cells entering the productive 
trajectory and the down-regulation of these same genes in cells entering the alternative trajectory. 
By analyzing the dynamics of gene expression changes along the productive trajectory (toward 
pluripotency) we demonstrate that changes in gene expression in the stochastic phase of 
reprogramming are not simply gradual and random; rather, genes are activated and inactivated at 
specific points during the progression from fibroblast to iPSC. Coupling single-cell transcript 
profiling with mathematical modeling we show that the gradual acquisition of pluripotency gene 
expression during reprogramming occurs as an ordered, probabilistic, gene-specific process that 
shows no signatures of interdependence between genes. This finding is consistent with the 
hypothesis that gene-specific chromatin states in the starting cells control gene activation 
dynamics during the reprogramming process. Our map of reprogramming also provides a robust 
model that can be used to dissect the precise mechanisms and chromatin modifications that limit 
the rate and efficiency of conversion of somatic cells to iPSC. This work represents a rigorous 
single cell transcript analysis of the reprogramming process in human cells and lays the 
foundation for the precise measurement and mechanistic dissection of this critical rate-limiting 
step in reprogramming. 
2.2 Results 
2.2.1 Experimental Design 
In this report we combine qualitatively and quantitatively robust single-cell transcript 
profiling 126  with FACS to measure the progression of individual MRC-5 human fetal lung 
fibroblasts through the reprogramming process. To make our results as broadly relevant as 
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possible we used viral delivery of the OSKM transgene cocktail, the most widespread method 
applied to human cell reprogramming 28,127. At select time points after transduction, cells were 
dissociated, stained, analyzed and collected by FACS. FACS markers used in this study include 
GFP (virus derived), αSSEA4, αTRA-1-60, and αCDH1 (see Materials and Methods). These 
markers were essential and allowed for enrichment of the rare cells exhibiting hallmarks of 
productive reprogramming. For example, SSEA4 and TRA-1-60 routinely provide ~30 and 3,000 
fold enrichment, respectively (data not shown). While very few SSEA4+ cells are likely to 
become true iPSCs, they provide a measurement of cells that have begun to exit the fibroblast 
state in response to OSKM transduction. In contrast, isolation of TRA-1-60+ cells later in 
reprogramming (Day 14) is likely to yield a large number of cells destined to become iPSC. In 
fact, >90% of these cells remain TRA-1-60+ after sorting and subsequent culture and this 
stability of the TRA-1-60+ phenotype has been shown to be a major determinant for the potential 
of cells to become iPSC 57. Single cells with defined FACS phenotypes were collected into cell 
lysis buffer and subject to single-cell RT-qPCR as previously described 126 (Figure 1A and 
Supplemental Figure 1). Throughout the course of this study we isolated and pre-screened 576 
cells in total, using 172 cells that passed quality control for our final analysis (see Materials and 
Methods and Supplemental Table 1). This includes many partially reprogrammed cells, as well 
as an un-transduced set of MRC-5 fibroblasts and H9 human embryonic stem cells (H9-hESC), 
which represent the beginning and end states of the process, respectively. 
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In order to monitor progress toward pluripotency, and away from the fibroblast state, we 
assembled a 48-gene qPCR panel including genes expressed in fibroblasts 55,128,129, a large 
number of genes involved in the maintenance of pluripotency (including various chromatin 
modifiers) 122,130–132 and genes previously suggested to be intermediate markers of the 
reprogramming process 9,49. For a complete list of qPCR markers see (Figure 1B and 
Supplemental Table 2). Initial visualization of the full dataset by unsupervised hierarchical 
clustering reveals that our FACS sorting strategy, and qPCR marker panel, isolates statistically 
separable populations that capture a range of transcriptional phenotypes between the fibroblast 
and pluripotent states (Figure 1C). We then performed a series of statistical analyses to: 1) 
describe probable trajectories followed by OSKM-infected cells; 2) measure the progress of 
cellular transcriptional profiles toward a pluripotent transcriptional phenotype; and 3) determine 
the order of gene activation during the reprogramming process. 
2.2.2 Mapping the Trajectory of OSKM-Infected Cells Throughout 
Reprogramming 
As a first step in visualizing our single cell transcription dataset, we used principal components 
analysis (PCA) to assess the complexity and major sources of variation in gene expression between all 
cells collected in our study. This analysis reveals that the first two PCA dimensions account for 33.1% of 
the observed variation, where PC1 primarily represents a cell’s distance from hESC, and PC2 primarily 
captures distance from fibroblasts (Figure 2A). In addition, these two axes appear to represent distinct 
trajectories followed by cells transduced with OSKM The first is a roughly linear productive trajectory 
between the fibroblast and hESC groups (R2=0.60, Figure 2B) and the second is an orthogonal trajectory 
leading away from fibroblast but not towards a pluripotent phenotype (herein referred to as the alternate 
trajectory, or ALT). Because the productive and alternate trajectory are well correlated with the PC1 and 
PC2 dimensions respectively (Figure 2C) and capture much of the variation in our dataset, we developed 
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a metric to analyze our data in a 2-dimensional Euclidean space that maps each cell’s distance (relative 
similarity) to the centroids of both the Fibroblast and hESC groups. In addition, we construct a Euclidean 
diagonal between Fibroblast and hESC which we term the “reprogramming progression axis”. This axis 
serves as a useful measurement of a given cell’s progression towards pluripotency and is a metric used in 
all subsequent analysis presented here. 
It is important to note that our analysis constructs likely reprogramming trajectories by sampling 
partially reprogrammed cells. This approach is common among many efforts to sample dynamic 
processes and is particularly ubiquitous in attempts to dissect the reprogramming process9,49,74. We apply 
the standard parsimonious assumption that the shortest path defined by these samples represents the most 
likely trajectory of the process. One caveat of this approach is that we cannot exclude the possibility that 
progression within the observed state-space is non-linear, and may be complex and/or cyclical. These 
possibilities will need to be ruled out with longitudinal live cell studies beyond the scope of this work. 
Another important consequence is that while cells clearly take time to traverse the trajectory, we do not 
expect progress along a trajectory to have a linear relationship with time. However, progress may be 
loosely thought of as a surrogate for time but should not be strictly interpreted as such. 
 Interestingly, when mapping the FACS-sorted phenotypes onto our Euclidean similarity graph 
we noticed that, while SSEA4 and TRA-1-60 appear in the expected order (SSEA4+ before TRA-1-60+), 
the SSEA4+ and SSEA4+/TRA-1-60+ populations exhibit considerable transcriptional heterogeneity 
(Figure 2D). SSEA4 positive cells are found in both the productive and alternative trajectories suggesting 
that, while SSEA4 may be a reliable marker of exit from the fibroblast state, it does not necessarily 
indicate that cells have moved toward a pluripotent transcriptional phenotype. Even more pronounced is 
the diversity of TRA-1-60 positive cells. The transcriptional phenotype of these cells extends from a 
nearly fibroblast-like profile, to a nearly ESC-like profile. The extremely high degree of transcriptional 
heterogeneity we observe, even within well-defined and widely utilized FACS profiles, underscores the 
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utility of single cell analysis to dissect fine differences in gene expression between partially 
reprogrammed cells.  
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With the phenotypic diversity of commonly utilized cell surface markers in mind, we utilized a 
Self-Organizing Map (SOM) to identify separable groups along the two previously described 
reprogramming trajectories in both PCA and Euclidean space (Figure 2E and F, respectively). Four of 
these groups (Fib, Early, Late and Pluri) lie along the productive trajectory from Fibroblast to ESC and 
the fifth encompasses cells in the alternate trajectory. It is important to note that while these groups can be 
statistically distinguished from one another, we do not believe these represent discrete stages in the 
reprogramming process. Further inspection reveals that progression along the productive trajectory is 
characterized by the consolidation of chromatin modifier expression, an increased probability of 
pluripotency gene expression, a progressive decrease in the expression of fibroblast markers and transient 
expression or repression of predicted intermediate markers 9,11. Among the earliest distinctions between 
the productive and alternate trajectories (Early vs Alt) is the induction of chromatin-modifying enzyme 
expression. While many of these genes are expressed at low levels in fibroblasts, they are coordinately 
up-regulated in the “Early” group, and become expressed at uniformly high levels in all cells progressing 
towards pluripotency. In contrast, cells in the alternate trajectory down-regulate or eliminate expression of 
these genes (Fig. 2G). In addition, “Alt” cells fail to upregulate the expression of early pluripotency genes 
(Figure 2H) and are found at all of the time points examined, suggesting that these cells are unlikely to be 
on a trajectory that ultimately leads to pluripotency. Because “Alt” cells appear to be following an 
orthogonal trajectory that may lead to fates unrelated to ESC (such as transformation or apoptosis 4,133) 
they were excluded from further analysis of the productive reprogramming trajectory.  
Taken together these data indicate that OSKM infected cells exit the fibroblast state along two 
distinct trajectories, and that the upregulation of chromatin modifiers marks a key early step towards 
successful reprogramming. The rapid upregulation of chromatin modification genes is consistent with the 
need for extensive chromatin remodeling prior to establishment  of the endogenous pluripotent GRN 
5,18,72. 
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2.2.3 Mapping Coarse Changes in Gene Expression along the Productive 
Trajectory 
In order to provide a rough benchmark for other literature examining transcriptional 
changes in ensemble samples of partially reprogramed cells, we identified quantitative 
expression differences between SOM groups along the productive trajectory (Figure 3). It is clear 
from this data that specific changes in gene expression occur along different portions of the 
trajectory, which suggests an underlying order to the gradual acquisition of pluripotency gene 
expression during the reprogramming process. However, closer analysis reveals that there does 
not appear to be tight covariance between genes activated along the progression toward 
pluripotency. Representative bubble plots illustrating transcript presence and absence (Figure 3 
and Supplemental Figure 2) show that genes being activated during reprogramming exhibit a 
period of heterogeneity in transcript detection prior to being detected in all cells approaching 
pluripotency. Quantitative analysis of gene expression levels also supports this finding (Figure 3, 
Supplemental Figure 3). These plots depict gene expression levels on the y-axis, overlain with a 
distribution graph showing the range of expression values within the population. A unimodal 
distribution indicates uniform expression around a mean within the population, whereas a 
bimodal distribution demonstrates a transcriptionally heterogeneous population (e.g. high/low) 
for the gene in question. Nearly all the genes in our study exhibit this bimodal behavior at some 
point along the reprogramming trajectory, before achieving a unimodal distribution as they 
approach the fully reprogrammed state, however the point of bimodality varies in a gene-specific 
manner. These findings demonstrate that the activation or inactivation of gene expression during 
reprogramming proceeds through a probabilistic intermediate step, resulting in transcriptionally 
heterogeneous cell populations, and that the timing of this transition occurs with gene specific 
dynamics.   
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In order to scan for potential differences in reprogramming gene expression dynamics 
between species (mouse and human) we processed our data so that it would be roughly 
comparable to that generated by Polo et al 8. As in the present study, Polo and coworkers used 
FACS to isolate and measure the transcriptional profiles of a large number of partially 
reprogrammed mouse fibroblasts and clustered genes based on their expression dynamics. We 
compared these clusters to the dynamics of the human orthologs 122,130 represented in our dataset 
(Supplemental Figure 4). While high-resolution comparison was not possible with the publically 
available mouse data, most genes shared between datasets appear to exhibit similar dynamics in 
the stochastic phase. That is, early mouse genes change expression early in the human trajectory, 
while late genes change later in the trajectory. However, despite the coarse limits of resolution in 
this comparison, several genes, including NANOG, LIN28A, POU5F1 and STAT3, appear to 
change at different stages of the reprogramming process in these two species. These disparities, 
while requiring more direct comparison and detailed confirmation, are consistent with distinct 
differences between regulation of the pluripotent state in mouse and human cells as well as 
probable differences in the starting chromatin state of loci in mouse and human fibroblasts.  
2.2.4 Reprogramming is a Loosely Ordered Probabilistic Process 
Effectively Modeled by Gaussian Distributions 
Our observation that distinct transcriptional differences exist between PC-SOM clusters 
indicates that gene expression changes during the stochastic phase of reprogramming appears to 
occur in an ordered fashion. However, the coarse grained nature of this differential analysis 
between statistically identifiable, but not necessarily biologically relevant groups, provides little 
insight to the exact nature of the order of gene expression dynamics during the stochastic phase. 
In particular, we wanted to address two specific questions: 1) Is the acquisition of pluripotency 
gene expression random and gradual, with all genes approaching a pluripotent profile at a 
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uniform rate over the course of the process?; and 2) Is there sub-structure within the patterns of 
gene activation that would suggest the activation of modules within the pluripotency GRN? We 
addressed these questions by differentiating between null and alternative hypotheses (in the form 
of distribution models) predicting gene expression frequencies along the reprogramming 
trajectory from MRC-5 to H9-ESC and comparing these to what we observe in our experiments. 
In order to formally address the first question we modeled random gradual change in 
gene expression by assigning each fibroblast and pluripotency marker a uniform rate 
(probability) of change along the trajectory from MRC-5 to H9-ESC that would result in 
predicted gene expression frequencies that match the observed frequencies at the start (MRC-5) 
and end (H9-ESC) of the process 8. In contrast, our alternative hypothesis was that genes change 
expression at specific stages of the process; in other words, gene expression during the stochastic 
phase is ordered. This alternative scenario was modeled by fitting Gaussian probability 
distributions to each gene such that the probability distribution was centered at the point of 
greatest change in gene expression frequency along the reprogramming trajectory. In order to 
model the behavior of transient genes, and to help calibrate differences between goodness of fit 
between models, we also built more complex models with two probability distributions, which 
allowed us to model genes that change expression at two points in the process. Changes in gene 
expression frequency predicted by our null model are linear, while the alternative model with 
one probability distribution predicts sigmoidal changes and the two distribution model allows for 
more complex dynamics of change in gene expression frequency, such as transient activation or 
inactivation. The goodness of fit of each model to our observed data was then measured for each 
gene in both PCA and Euclidean space using an F-test statistic. Because goodness of fit typically 
scales with the number of parameters in a model, the Gaussian models were penalized for added 
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parameters using a corrected Akaike Information Criterion (AIC, see Materials and Methods). 
The results of these tests can be found in (Figure 4A-D and Supplemental Table 3). 
As demonstrated in Figure 4B, the vast majority of genes reject the null hypothesis (F-
statistic > F-Critical) in favor of a Gaussian model. Note that many genes that reject the null 
hypothesis do so very strongly, while the few genes that better fit linear dynamics do so only 
marginally (Figure 4C). In addition, most genes that do not reject the uniform model exhibit little 
or no change over the course of reprogramming or have noisy expression profiles. Both of these 
observations suggest that most gene expression changes occurring during the stochastic phase are 
not simply gradual acquisition of an ESC-like expression frequency, rather they turn on and off 
at specific points in the process. 
To further assess the confidence with which random change (uniform probability 
distribution) in gene expression during the stochastic phase can be rejected by our models 
(Gaussian probability distribution) is to compare the explanatory power of each model, as 
adjusted for the additional parameters required in each more progressively complex scenario. 
Figure 4D shows that while one normal distribution significantly improves AIC (lower is better), 
two normal (or even three normal - data not shown) do not add much explanatory power. One 
exception is for genes that exhibit transient expression changes, the fits for which are shown in 
Supplemental Figure 5. For this reason, we suggest that gene expression dynamics during the 
stochastic phase are best described as events occurring at specific points in the process, where 
most gene’s expression dynamics are well described by a single normal probability distribution 
centered at the point of maximal rate of change. Genes that change at very specific points in the 
process have very tight probability distributions, while genes with less precise dynamics display 
broader probability distributions (approaching the uniform distribution of our null model).  
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In order to compare dynamics between genes, we modeled each gene in our study using 
single Gaussian probability distributions as described above. All model fits are illustrated in the 
Supplemental Figure 6. One example fit is illustrated for CDH1 in Figure 5A. In this figure the 
black dots represent measured expression frequencies of CDH1 in sliding windows along the 
inferred reprograming trajectory. The red curve shows gene expression dynamics modeled as a 
Gaussian probability distribution fit to the experimental data and the blue line illustrates 
expression frequencies predicted by that probability curve.  
When the dynamics of several genes are compared in one graph (Figure 5B-E) it is 
readily apparent that: 1) genes are activated or inactivated at different points during the 
reprogramming process; 2) genes have specific stringencies in their activation dynamics (some 
genes change at fairly specific stages, while others change over almost the entire course of the 
process); and 3) there is considerable overlap in the expression probabilities of individual genes. 
Most genes are activated or repressed with diffuse dynamics, while several (NANOG, CDH1, 
ZFP42, ZIC3 and OTX2) change at more specific stages of the reprogramming process. The 
diffuse dynamics and broad windows of activation observed for most pluripotency markers is 
consistent with the longitudinal observation that the expression of the surface antigens SSEA4 
and TRA-1-60 in iPSC colonies are not strongly predictive of successful reprogramming events 
49,51.  Taken together, this data strongly supports the hypothesis that rather than being a strictly 
ordered or strictly random process, the stochastic phase of reprogramming is an ordered 
probabilistic process. Seen in this light, prior ordered and random models can be coherently 
united  56,124,134. 
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2.2.5 Changes in Pluripotency Gene Expression During the Stochastic 
Phase Do Not Show Hallmarks of Activation of the Pluripotency Gene 
Regulatory Network 
Having observed ordered dynamics in the stochastic phase, we sought to determine if 
there was any indication that this order might arise from the partial activation of the endogenous 
pluripotency GRN. Current models suggest that partially reprogrammed cells enter a late, rapid 
deterministic phase that is controlled by activation of the endogenous pluripotency GRN and 
may be marked (in mouse cells) by the activation of the endogenous Sox2 locus56,135. 
Alternatively, order could emerge gradually or piecemeal during the stochastic phase. A 
hallmark of concerted gene regulation as exerted by a GRN, is strong correlation (or anti-
correlation) between gene expression patterns 8,110,124. Our model provides a powerful way to 
detect correlated gene expression that lies above the background correlations inherent during 
reprogramming (i.e. pluripotency markers all become expressed in fully reprogrammed cells). In 
this case, our null hypothesis is that during the stochastic phase there is no dependency between 
genes and that all correlation between gene expression in individual cells results simply from the 
increase in frequency of pluripotency markers as cells approach an ESC-like transcriptional 
profile. Our alternative hypothesis is that some pluripotency genes may be co-regulated (or 
cross-regulate) during the stochastic phase and would thus display higher than background levels 
of co-expression (as measured by correlation). To test these hypotheses we used the probability 
profiles of each gene to generate a simulated data set in which gene expression is determined 
only by the probability profile of each gene, with no dependencies between genes. The resulting 
dataset accurately recapitulates the individual dynamics of each gene in our dataset, and provides 
pairwise correlation values that are solely dependent upon the convergence of all pluripotency 
markers on uniform expression in ESC. We then compared pairwise correlations between genes 
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in this background data set with the real correlations observed in our single-cell transcript data 
(Figure 6).  
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Interestingly, the only correlations we find rise above background expectations occur 
between a set of chromatin regulators that distinguish between entry into the productive 
trajectory and entry into the alternative trajectory (Figure 6). This coordinated activity is likely 
the result of activation of the c-MYC GRN, which is known to be activated upon OSKM 
induction, and is largely limited to genes with a permissive chromatin state in fibroblasts as is the 
case for many chromatin modifier genes 136,135 (Figure 6, inset). In contrast, none of the 
correlations between members of the pluripotency GRN rise above background expectations, 
despite their overall increase in expression frequency as cells approach an ESC-like expression 
profile. We therefore accept the null hypothesis: that despite the ordered activation of genes in 
the pluripotency GRN during the reprogramming process, there is no evidence for gradual or 
modular activation of the pluripotency GRN during the stochastic phase of reprogramming. An 
important corollary that follows from this result is that the dynamics of gene activation during 
the stochastic phase appear to depend only upon the local properties of each gene, rather than the 
sequential activation of precursors in the GRN. Of course, the numbers of genes we analyze in 
our study somewhat limits the power of this analysis, and a more comprehensive single-cell 
study measuring many more genes might uncover obligate relationships between genes that are 
not apparent in our core pluripotency GRN gene set. 
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2.3 Discussion 
In this study we present a rigorous single cell analysis of reprogramming in human cells and 
show that the stochastic phase of reprogramming of human fibroblasts by OSKM is an ordered 
probabilistic process which can be simply modeled using independent Gaussian distributions. An 
advantage of our approach lies in the fact that it makes no a priori assumptions about the 
progression of cells toward pluripotency, based on time or surface marker expression, both of 
which are poor indicators of reprogramming progress. In addition, the simplicity of our model 
and its exceptional fit to our observed expression dynamics provide a tractable framework for 
further dissecting the rate-limiting aspects of reprogramming. The results of this work also unify 
existing ordered and random models of the stochastic phase of reprogramming 11,49,52,55,110,123 and 
are consistent with observations from both population level and single cell studies of gene 
expression changes during reprogramming 9,49,56. The ordered nature of the stochastic phase is 
readily apparent in the distinct, gene-specific expression dynamics we observe during 
reprogramming, while the probabilistic nature of the process is evident in broad gene-specific 
expression dynamics over large portions of the reprogramming trajectory (Figure 5 and Figure 
7), and the apparently independent control of gene expression dynamics during the stochastic 
phase (Figure 6). These findings are consistent with a recent study by Tanabe et al. 57 that 
suggests the TRA-1-60+ phenotype is unstable and transcriptionally heterogeneous and that 
stabilization of the TRA-1-60+ population is a critical rate limiting step in reprogramming. Note 
we suggest retaining the term “stochastic” for this phase of the reprogramming process, in that 
stochastic can be used to describe ordered probabilistic events, and does not necessarily imply 
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complete randomness. The use of the term stochastic is especially appropriate given the 
independence of activation dynamics of key genes in the core pluripotency GRN. 
One consequence of the independent activation of genes during reprogramming is that an 
extremely wide variety of cell states are present during the reprogramming process, which gives 
the overt appearance of disorder. Thus, while any given partially reprogrammed cell’s gene 
expression pattern may appear to be random, the probabilities of expression of individual genes 
are clearly biased towards specific points along the reprogramming trajectory. One implication 
of these findings is that any single marker is unlikely to be effective at determining the extent to 
which a given cell has been reprogrammed 49,137.  
We note that variations in the cell cycle could contribute to the transcriptional 
heterogeneity of a subset of genes in our dataset. However recent studies in hESC have shown 
that the transcription of genes associated with pluripotency does not fluctuate during the cell 
cycle 138, suggesting that cell cycle status is unlikely to have a major impact on our analysis of 
the activation of the pluripotency GRN. In addition, the persistence of cyclin transcripts 
throughout the cell cycle and their considerable post-transcriptional regulation in ESC’s 139, 
precludes strong inference of cell cycle status from transcriptional measurement of a single cell-
cycle regulator.  
Another possible source of transcriptional heterogeneity between partially reprogrammed 
cells in our cultures could be the delivery of O, S, K, and M on individual vectors (as is standard 
in widely utilized human reprogramming protocols). However the broad agreement of expression 
dynamics over the course of reprogramming between our results using individual viral delivery, 
and those reported by Polo et al using an inducible, polycistronic construct in a clonal cell line, 
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suggests that viral heterogeneity does not fundamentally affect the order of gene expression 
dynamics, or the shape of the trajectory of cells undergoing the reprogramming process. 
Furthermore, the initial description of the highly heterogeneous nature of the stochastic phase by 
Buganim et al was also derived from data using clonal cells expressing OSKM from an inducible 
polycistronic OSKM construct. Thus, the stochastic nature of this phase does not appear to be a 
direct consequence of OSKM heterogeneity. However, these results do not rule out the 
possibility that each of the OSKM factors have distinct roles in various stages of the 
reprogramming process, nor that heterogeneity in OSKM content will be observed across the 
partially reprogrammed population of cells. Indeed, understanding the role of each factor in the 
reprogramming process and the critical window for the action of each represents an important 
goal of future work.  
A likely explanation for the apparent lack of deterministic behavior during the stochastic 
phase may be the existence of as yet unidentified, gene-specific factors that restrict the rate of 
transcription activation by OSKM. One compelling candidate for these factors is the local 
chromatin architecture of the pluripotency genes in the starting somatic cell type. Indeed, 
epigenetic remodeling was implicated as a major rate limiting step in even the earliest days of 
somatic cell reprogramming using nuclear transfer 21,125 and is almost certainly one of the most 
important probabilistic events limiting the rate and efficiency of reprogramming. Many reports 
have experimentally validated this hypothesis by demonstrating that global chromatin 
reorganization is critical for successful reprogramming 5,50,66,69. Because many of the required 
changes in chromatin state appear to occur in a slow and probabilistic fashion 43,140,141 it is likely 
that these changes limit the rate at which exogenous OSKM can activate the endogenous 
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pluripotency GRN thus limiting the efficiency and speed of reprogramming and endowing the 
majority of the process with stochastic dynamics.  
Our finding, that enhanced expression of chromatin modifiers is a hallmark of entry into 
productive reprogramming complements several studies demonstrating that successful 
reprogramming requires the gradual erosion of epigenetic barriers to activation of the 
pluripotency GRN by OSKM 4,5,65,67,69. This event is likely governed by the activity of c-MYC, 
which together with KLF4, acts early in reprogramming to activate loci with permissive 
chromatin states, including many chromatin modifier loci in fibroblasts 66,67. In addition, many 
treatments known to enable chromatin remodeling have been shown to enhance the rate and/or 
efficiency of the reprogramming process 61,65,142,143, while, conversely, knocking down factors 
required for such epigenetic changes can inhibit or prevent successful reprogramming 
61,65,111,142,144,145. However, with the exception of some very early events 66,67 the order and 
precise identity of chromatin modifications required for successful reprogramming is not yet well 
known. By precisely describing and modeling gene expression dynamics during the stochastic 
phase the present study provides a quantitative framework for dissecting these key rate limiting 
steps and will enable the mechanistic dissection of interventions known to accelerate or enhance 
the efficiency of the reprogramming process. 
Chapter 3 Comparison of Monocistronic and Polycistronic Reprogramming 
Methods in Two Cell Types 
 
3.1 Introduction 
 Reprogramming terminally differentiated cells to a pluripotent state by exogenous expression of 
the Yamanaka factors OCT4, SOX2, KLF4 and c-MYC (OSKM) has the potential to revolutionize many 
aspects of modern medicine. However, despite years of research this process remains highly inefficient 
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and produces considerable cellular heterogeneity, problems that must be overcome before this technique 
can be used clinically.  In the years following the first reports of OSKM-mediated reprogramming, 
several methods have been developed to reprogram cells to pluripotency in an effort to increase the 
efficiency and quality of iPSC generation. This includes using different methods of delivering the OSKM 
factors, including retroviral, lentiviral and episomal vectors, mRNA/miRNA transfection, as well as the 
use of additional factors such as NANOG, LIN28, SALL4 and others 6,31,38,77,146. While many of these 
approaches have increased the efficiency and/or rate of reprogramming, at present it is unclear how these 
results manifest at the molecular level and such knowledge could provide insight into common 
mechanisms necessary to acquire pluripotency.  
Many efforts to illuminate the molecular underpinnings of reprogramming have been complicated 
by the inefficiency and temporal asynchrony of the process.  Only 0.01-1% of cells reaches the 
pluripotent state and do so at different rates over the course of a 3-4 week period. As a result, the majority 
of studies conducted to date that rely on bulk measurement of heterogeneous populations of cells are 
inherently biased towards analyzing unsuccessful reprogramming events. Thus, measurement of 
transcriptional or other events leading to pluripotency may be obscured. To overcome this limitation of 
bulk analysis our group and others have used single cell analysis and mathematical modeling to 
deconstruct the transcriptional and protein-level changes occurring in cells undergoing reprogramming 
10,56,58,147. By profiling individual cells en route to pluripotency we are better able to assess how the 
pluripotency gene regulatory network (GRN) becomes activated in response to the OSKM factors. 
Specifically, whether this activation happens as a series of concerted deterministic events, or occurs 
gradually over the length of the process. Equally important is the ability to measure what appear to be 
unsuccessful reprogramming events leading to trajectories other than pluripotency. Identification of 
common features in divergent cells can reveal events preventing cells from becoming iPSCs. 
This previous work proposed a model where acquisition of pluripotency is primarily limited by an 
early probabilistic or stochastic phase. During this phase, genes associated with pluripotency activate 
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independently , lacking coordinated expression characteristic of a stable, pluripotent state 11,55,56,134. This 
period can persist for a variable length of time, after which cells that have made the requisite epigenetic 
and transcriptional changes, activate the pluripotency gene regulatory network (GRN) and are stabilized 
in the iPSC state 56,91,148. The stabilization of this network requires precisely controlled levels of OSKM 
expression67,101. Premature inactivation of exogenous OSKM fails to generate iPSCs52,104 and conversely, 
failure to inactivate the OSKM cassette forces cells to an alternate ESC-like state, distinct from iPSC149. 
Given the relationship between factor stoichiometry and efficiency, it is important to assess how 
variations in reprogramming method impact the acquisition of pluripotency. 
Comparison of monocistronic and polycistronic viral delivery of the 4 factors is of particular 
interest, as this remains the most widely utilized reprogramming strategy in the human system2,150. 
Monocistronic delivery allows flexibility in the stoichiometry of factor delivery due to random integration 
of the individual constructs, however many cells receive combinations of factors that are suboptimal for 
reprogramming, or may cause cells to take a different trajectory to the pluripotent state101,151. In contrast, 
polycistronic delivery fixes the ratio of factor delivery at 1:1:1:1, a ratio that may not be optimal for 
successful reprogramming, but guarantees that all transfected cells will carry a full complement of the 
reprogramming factors. In separate studies it has been demonstrated that mono and polycistronic systems 
reprogram cells at different efficiencies in mouse, 0.01% and 0.5%, respectively, and human 0.2% and 
1.5%,respectively 2,28,32,33,145, however no direct comparison of these methods exists currently. 
Furthermore, species-specific differences in the molecular events leading to pluripotency exist between 
mouse and human152, further complicating the comparison of these two techniques and underscoring the 
importance of studying reprogramming in human cells for clinical purposes.  
The majority of studies to date have focused on reprogramming fibroblasts due to their simplicity 
of isolation, however dozens of other cell types have been successfully reprogrammed. The starting cell 
type has been demonstrated to have a significant effect on both the efficiency of the process, as well as 
the differentiation capacity of the resulting iPSCs. There is evidence to suggest that these effects are due 
43 
 
to unique epigenetic landscapes in different cell types which can affect the accessibility of pluripotency 
loci and consequently their ability to be activated by reprogramming factors5,50,69,153. This same epigenetic 
landscape also results in a ‘memory’ of the cell’s starting identity, making differentiation back to the cell 
type of origin more efficient than generation of more therapeutically relevant alternatives118,154,155. Thus, 
the starting cell type can have a dramatic influence on the outcome of the reprogramming process but 
again, no analysis of whether this affects the acquisition of pluripotency has been performed. 
In this study, we apply single cell transcript analysis to compare the transcriptional dynamics 
underlying the acquisition of pluripotency in monocistronic and polycistronic OSKM systems. These two 
delivery methods were tested in both MRC-5 and BJ fibroblasts. We demonstrate that polycistronic viral 
delivery produces significantly higher reprogramming efficiencies compared with monocistronic delivery 
and that this effect is due in part to premature inactivation of the individual O, S, K or M vectors in the 
monocistronic method. In addition, we show that the activation of key pluripotency loci such as NANOG, 
OCT4, LIN28 and DNMT3B occurs earlier in the polycistronic condition and that these cells progress 
more uniformly towards pluripotency. Finally, we compare polycistronic reprogramming between MRC-5 
and BJ fibroblast cells and reveal that while the order of gene activation is similar between cell types, 
MRC-5 and BJ cells take divergent paths upon factor induction, followed by convergence later in the 
reprogramming process.  
3.2 Results 
3.2.1 Monocistronic and Polycistronic Reprogramming Efficiency  
As an initial assessment of reprogramming efficiency between the monocistronic (Mono) and 
polycistronic (Poly) reprogramming methods, we analyzed the percent of SSEA4 single-positive (S+T-) 
and SSEA4/TRA-1-60 double-positive (S+T+) cells by FACS, markers associated with early and late 
reprogramming respectively49,51,137.  We observe a significant enrichment of S+T- cells in the Poly, 
compared with the Mono condition which increased from a 2-fold difference at D4, to >8-fold at D14. 
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This trend is apparent for TRA-1-60+ cells as well, where Poly exhibits ~15-fold increase at both time 
points analyzed (Figure 8C). To determine whether the difference in SSEA4 and TRA-1-60 expression 
between conditions correlated with reprogramming efficiency, we stained and counted AP+ colonies at 
D21 and D28. Poly cells have 10-fold more AP+ colonies than Mono cells at D21, and this increase is 
even more pronounced at D28, the point at which colonies are typically picked to establish iPSCs (Figure 
8D). This corresponds to an efficiency of ~5% and 0.5% for Poly and Mono, respectively. This is 
consistent with previous reports showing a 10-fold increase in reprogramming efficiency between the two 
conditions, albeit in separate studies2,146,150.  In our experience, Mono colonies tend to be broad and cover 
more area than Poly colonies which are small and punctate. Example colonies are shown in Figure 1B. To 
ensure this difference in morphology did not skew our colony counting results we also measured the total 
area of the plate covered by AP+ cells. We still observe significantly higher AP-positivity in Poly 
compared with Mono (Figure 8E). These findings also hold true in BJ fibroblasts reprogrammed with 
Mono and Poly as shown in Supplemental Figure 7.  
3.2.2 Experimental Design 
In order to measure transcripts in individual cells at various points in the reprogramming process, 
we infected MRC-5 fibroblasts with a polycistronic construct containing all four Yamanaka factors 
(Poly). We then isolated cells by FACS at D4, D7, D11, D14 and D21 using the surface markers SSEA4 
and TRA-1-60 to enrich for early (SSEA4+/TRA-1-60-) and late (SSEA4+/TRA-1-60+) reprogramming 
events, respectively (Figure 8A). These cells were sorted into 96-well PCR plates and processed through 
our single cell pipeline and qPCR was performed on the Fluidigm Biomark against a panel of 96 markers 
(Supplemental Table 4). In addition to profiling 80 reprogramming cells, we also profiled 16 MRC-5 
fibroblasts and 32 H9 and H1 hESCs to represent the beginning and end points of the process, 
respectively (Supplemental Table 5). The Poly dataset was trimmed for comparison with our previously 
published MRC-5 Mono data which contains cells sampled at days 4, 7 and 14, measured for the 
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expression of 48 genes, all of which are present in the larger 96 gene panel analyzed in the Poly 
experiment149. 
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3.2.3 Progression of Individual Cells in Mono and Polycistronic 
Reprogramming 
To visualize the progression of cells from the fibroblast to the pluripotent state, we used our 
previously described method of plotting cells based on their relative distance from both the fibroblast and 
hESC populations149 (Figure 9A), overlaid with the surface markers used to isolate the cells. This method 
is agnostic to the time point of collection since progression through the reprogramming process is 
asynchronous and poorly correlated with time58. Using this approach, we observe a striking increase in 
progress of S+T- cells in the Poly condition, with some cells overlapping the hESC population, whereas 
S+T- Mono cells are only present in the first half of the reprogramming trajectory. We also notice that 
S+T+ Poly cells are very tightly clustered around the hESC population while S+T+ Mono cells span a 
large portion of the reprogramming trajectory. The increased progression in the Poly condition is 
accompanied by greater reprogramming synchrony compared with Mono, as revealed by the tighter 
distribution of cells along the reprogramming trajectory, maintained over time (Figure 9B). The 
distribution of S+T- Mono cells across the reprogramming trajectory broadens between D4 and D14, 
suggesting that either some cells are initiating reprogramming at the later time point, or that not all cells 
expressing SSEA4 are progressing through the process at the same rate, commonly referred to as variable 
latency. This is in contrast to Poly cells, which all progress towards an ESC-like transcriptional profile by 
D14.  
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3.2.4 Generating a Logistic Regression Model 
It has been proposed that the period of variable latency results from the stochastic and 
uncoordinated activation of pluripotency loci required to drive cells towards the pluripotent state. Because 
cells reprogrammed by the polycistronic method progress more uniformly towards the ESC state than 
monocistronic reprogramming cells, we asked whether the activation of pluripotency loci, or inactivation 
of fibroblast-associated loci, was more tightly coordinated in Poly cells. To this end, we improved upon 
our published method 149(Methods) to model the expression changes of genes along the reprogramming 
trajectory from fibroblast to hESC. Our new method gains higher accuracy while reducing the number of 
parameters to minimize bias compared with our previous model. We define the reprogramming trajectory 
by projecting cells into a 2-dimensional PCA space and fitting a polynomial curve through the dataset. 
We then find the shortest distance from each point to the curve and assign a value for that cell along the 
trajectory. These values are scaled between 0 and 1, representing the beginning and end of the process, 
respectively. For each gene in our dataset, we reduce the data to presence/absence calls and fit a logistic 
regression to the data, representing a continuous measure of the probability of detecting a given gene over 
the course of reprogramming. In addition, we gain information about when a gene is activated in the 
majority of samples and how rapidly that change occurs based on the point of greatest change in 
probability and the steepness of the curve. An example fit curve is shown in Figure 10A with dashed lines 
representing bootstrapped confidence intervals around the fit curve. Model fits for all genes can be found 
in Supplemental Figure 8. The expectation of this model is that conditions where gene expression changes 
rapidly correspond to a reprogramming process with fewer barriers to the transcriptional 
activation/inactivation events necessary to reach pluripotency and more closely resembles a deterministic 
rather than probabilistic process.  
3.2.5 Assessment of Two Reprogramming Methods Using a Logistic 
Regression Model 
To compare the model fits between conditions we separated activating and inactivating genes and 
plotted the point of greatest slope and the bootstrapped confidence intervals in Figure 10B. We notice 
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significantly earlier points of activation in Poly compared with Mono reprogramming (Figure 10C and E) 
for a subset of genes in our panel. This includes several key pluripotency loci such as POU5F1, NANOG 
and DNMT3B and may in part explain the improvement in reprogramming efficiency. Interestingly, 
despite earlier changes in gene expression in Poly cells, the order in which these genes are 
activated/inactivated is strongly correlated between the two conditions (Spearman’s r = 0.75). This is 
further supported by the high correlation of gene loadings from independent PC analysis of Mono and 
Poly cells in the PC1 dimension (Figure 10D). The loadings provide a measure of when and how strongly 
each gene contributes to progression through the process and therefore, strong correlation in the loading 
scores indicates a common path to pluripotency for Mono and Poly reprogramming. It is important to note 
that while the two methods as a whole follow a similar path to the pluripotent state, the activation of a 
given gene remains a probabilistic event under our model. Thus, the order in which an individual cell 
activates/inactivates these loci is not fixed (ie is not deterministic).  Consistent with this notion, we do not 
see a narrowing of the activation window as there is no significant difference in the slope of the activation 
curves between conditions (Figure 10F), nor do we observe increased correlation between genes in the 
Poly condition (Figure 11A-C). Taken together, these results suggest that while some pluripotency genes 
are activated earlier in the process in Poly reprogramming, coordinated GRN activity or deterministic 
behavior is not observed. 
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3.2.6 Heterogeneous Expression of Exogenous OSKM Factors 
Given that gene activation/inactivation is only slightly enhanced in polycistronic reprogramming 
and that the overall dynamics of the process appear similar between conditions, we looked for other 
factors contributing the poor efficiency of Mono reprogramming in both MRC-5 (Figure 12) and BJ 
(Supplemental Figure 9) fibroblasts. We hypothesized that OSKM heterogeneity could contribute to the 
low efficiency of Mono reprogramming since the factors are delivered on separate viral particles. To this 
end, we included SYBR primers targeting synthetic 3’-UTR regions present in the individual OSKM 
constructs (Supplemental Table 6) allowing us to measure the expression of the transgenes in all single 
cells collected for this experiment in addition to the 48-gene panel analyzed above. Looking at all four 
factors collectively it is apparent that a vast minority of cells express all four exogenous factors, with 
most cells expressing only one or two of the transgenes, including cells close to the hESC state (Fig 12A). 
Interestingly, cells that express the full complement of reprogramming factors are clustered early in the 
reprogramming trajectory, with no 4-factor containing cells progressed beyond the 50% mark. In contrast, 
most cells late in the trajectory express only one or two factors, typically either OCT4, MYC or both (Fig 
12B). As expected, nearly all cells progressing along a previously described alternate trajectory away for 
both fibroblast and hESC lack expression of all reprogramming factors except MYC, illustrating the 
requirement of OSK expression for productive reprogramming.   
3.2.7 Expression Patterns of Endogenous and Exogenous OSKM in 
Monocistronic Reprogramming 
The considerable heterogeneity of transgene expression in Mono reprogramming cells led us to 
compare the expression of the endogenous (ENDO) and exogenous (EXO) copies of the OSKM factors to 
see if cells lacking transgene expression exhibited activation of the endogenous copy (Fig 12B). Nearly 
all Mono cells express exogenous MYC, while only three cells express the endogenous form. This can 
likely be attributed to the profound proliferative effects of high levels of MYC expression4,66,136,135, which 
results in expansion of this population and increases the likelihood they are sampled in our experiment. In 
contrast, EXO-KLF4 is detected in very few cells, however the endogenous form is present in the 
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majority of samples. This is consistent with the role of KLF4 in promoting MET, an essential step in 
reprogramming that occurs late in the process74,156,157.  Also, in agreement with previous reports that 
OCT4-high SOX2-low is an optimal factor stoichiometry for reprogramming58,101, we notice the 
expression of exogenous OCT4 and SOX2 exhibit opposite patterns, with EXO-SOX2 expressing cells 
confined to the first half of the reprogramming trajectory while EXO-OCT4 cells persist until the later 
stages of reprogramming (Fig 12B). In addition, many late-reprogramming cells expressed both the 
ENDO and EXO forms of OCT4 further supporting this notion. Surprisingly, ~50% of late 
reprogramming cells fail to express either ENDO or EXO-SOX2. In mouse, SOX2 is required for entry 
into the deterministic phase and stabilization of the pluripotent state. The absence of SOX2 in some of our 
late reprogramming cells begs the question of whether or not these cells will successfully reprogram. In 
addition, it is unclear whether these cells were capable of progressing to the late stages of reprogramming 
in the absence of SOX2 expression, or if the SOX2 virus was prematurely inactivated prior to completing 
the process.  
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3.2.8 Transcriptional Analysis of Low-GFP Reprogramming Cells 
To address this question we took advantage of the fact that our monocistronic OSKM vectors co-
express GFP along with each reprogramming factor, allowing selection of cells with low viral content as 
indicated by low-GFP expression. These cells were sorted by FACS and we assessed their transcriptional 
profile using our 48-gene panel. When added to our reprogramming trajectory (Fig 12C), these cells look 
nearly identical to fibroblasts and both S+T- and S+T+ Low-GFP cells exhibit impaired progression 
compared with their High-GFP counterparts (Fig 12D). This would suggest these cells failed to respond 
to the OSKM cocktail however, Principal Component Analysis reveals the Low-GFP cells are a distinct 
population and separate from non-reprogrammed fibroblasts along the PC3 axis (Fig 12E). This 
separation is due to the expression of the late reprogramming genes ZIC3 and OTX2 in these cells, 
despite the failure to activate core pluripotency loci including OCT4, NANOG, SOX2 and ZFP42 
(REX1) and the persistence of fibroblast gene expression (LOX and LUM) (Fig 12F). The expression of 
ZIC3 and OTX2 in the Low-GFP population indicates that these cells have reached the late stages of 
reprogramming, but collapsed back to a Fibroblast-like state due to premature loss of transgene 
expression. Alternatively, cells may have only been infected with a subset of the reprogramming factors, 
following a reprogramming trajectory not typical of cells receiving the full complement of OSKM.  
3.2.9 Reprogramming Using Three-Factor Combinations OSKM 
We tested this hypothesis explicitly by generating all possible 3-factor combinations (SKM, 
OKM, OSM and OSK), removing each factor from the STEMCCA polycistronic vector and measuring 
the reprogramming trajectory of infected cells. Attempts to reprogram cells with any of these 3-factor 
combinations failed to produce any AP+ colonies and resulted in a significant reduction in SSEA4+ cells 
(Supplemental Figure 10A). These cells also fail to productively reprogram, moving away from fibroblast 
but not towards hESC (Fig 13A) as evidenced by minimal expression of both fibroblast and pluripotency 
genes in our panel. This reduced expression is not due to lack of cell viability or the induction of 
apoptosis however, indicating these cells follow a trajectory that cannot be measured using our existing 
57 
 
marker set (Supplemental Figure 10B). K-means clustering of the 3-factor reprogramming conditions 
along with the MRC-5 Mono dataset reveals that this trajectory is equivalent to the Alternate trajectory 
we identified previously149 and suggests that Mono cells in this Alternate group are also cells that failed to 
receive the full complement of OSKM (Fig 13C).    
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3.2.10 Trajectory of BJ and MRC-5 Fibroblast Lines in Polycistronic 
Reprogramming 
Having determined that premature inactivation of the individual OSKM factors is a major 
weakness of Mono reprogramming, we turned our attention to comparing the dynamics of pluripotency 
gene expression between two fibroblast cell lines, BJ and MRC-5, using the polycistronic method. To this 
end, we compared MRC-5 and BJ cells reprogrammed with polycistronic OSKM and analyzed the 
expression of 96 genes (as described above). In our system, BJ fibroblasts exhibit ~3x greater efficiency 
than MRC-5, as determined by the number of AP+ colonies at days 7, 14, and  21  (Supplemental Figure 
7). Thus, we next sought to determine whether this difference in efficiency was evident in the trajectories 
of each reprogramming cell type, or in the expression of individual genes. Comparing the progression of 
cells over the time course of reprogramming shows little difference in the S+T- and S+T+ cells from both 
cell types and, as expected, S+T+ cells progress uniformly towards pluripotency, while S+T- exhibit a 
larger distribution due to variable latency(Fig 14 A-B). In addition, visualizing the trajectories in PCA 
space shows that the majority of the process looks identical between cell types in the first 2 PC 
dimensions, which cumulatively capture ~35% of the variance(Fig 14C). Including the PC3 dimension 
(5% variance) however, reveals a slight divergence of the two trajectories early in the process, followed 
by convergence near the hESC state (Fig 14D). This observation is reiterated by plotting each cell type 
side-by-side in its own PC space. An initial comparison of the PCA shows both cell types exhibit a 
similar distribution of reprogramming intermediates as determined by the amount of variation captured by 
each PC dimension (Fig 14E). Comparison of the gene loadings between the MRC-5 and BJ PC analyses 
reveals strong correlation in PC1 (Spearman r = 0.95) and PC2 (Spearman r = 0.72) dimensions, while 
correlation in PC3 is weak (Spearman r = 0.59) (Fig 14F). This again suggests nearly identical gene 
expression dynamics between the two cell types with subtle differences. 
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3.2.11 Gene Expression Dynamics in BJ and MRC-5 during Polycistronic 
Reprogramming 
To determine what genes specifically contribute to the slight differences in the reprogramming 
trajectories of BJ and MRC-5 fibroblasts, we utilized our model to compare the point of activation of 
genes between conditions. Example fit curves for increasing and decreasing genes are shown in Fig 15A 
and E, respectively. The complete set of fit curves is displayed in Supplemental Figure 11. We again use 
box and whisker plots to represent the mean and bootstrapped confidence intervals of the fit curves for 
both activating and inactivating genes (Fig 15B and F). A delay in the activation of several genes (Fig 
15B and D, red highlight) is immediately apparent in MRC-5 cells early in the trajectory. These include 
key pluripotency genes such as NANOG, POU5F1, DNMT3B and LIN28. As expected, genes late in the 
trajectory exhibit nearly identical activation patterns, consistent with the observation that the trajectories 
converge near the ESC state. We also observe delayed inactivation of the fibroblast marker LOX and an 
inhibitor of MET, SNAI2, in MRC-5 cells (Fig 15F and H, red highlight). For both activating and 
inactivating genes, we see the same degree of correlation between genes in both conditions (Fig 15C and 
G), indicating the interactions between genes are consistent in BJ and MRC-5 reprogramming.  
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3.3 Discussion 
In this study we performed a side-by-side comparison of Polycistronic and Monocistronic 
reprogramming in human fibroblast cells. Our primary finding is that reprogramming by the Polycistronic 
method results in a 10-fold increase in efficiency over Monocistronic reprogramming and that this 
difference is due in part to the premature inactivation of the individual OSKM factors in the 
Monocistronic condition. While it has been previously documented that factor expression decreases over 
the course of reprogramming52,158, this was thought to represent cells entering the pluripotent state. 
Inactivation of the reprogramming factors is generally considered to be a late event in the reprogramming 
process and is associated with the generation of stable iPSC lines49,97. Our study represents the first report 
that premature inactivation of OSKM can occur amidst productive reprogramming and results in a 
collapse of cells back to a fibroblast-like state. These cells exhibit signatures of productive 
reprogramming, in particular, the expression of the late reprogramming genes ZIC3 and OTX2, however 
they fail to activate the core pluripotency circuitry and continue to express markers of the fibroblast state. 
We exclude the possibility that these failed reprogramming events arise from cells receiving an 
incomplete complement of OSKM by demonstrating that cells lacking any one of the 4 factors fail to 
reprogram. Our analysis of transgene content in productively reprogramming cells demonstrates that a 
particular stoichiometry is optimal for pushing cells towards the pluripotent state. Specifically, high levels 
of OCT4 and low levels of SOX2 are favored in cells that have reached an ESC-like transcriptional 
profile, while KLF4 expression is consistent throughout the process, in line with previous reports58,151. 
The robust detection of MYC throughout the process is expected due to the rapid expansion of MYC 
expressing cells and this increase in cell cycling has been shown to greatly enhance the efficiency of 
reprogramming135. Importantly, it has been previously shown that there is no selective inactivation of any 
of the 4 reprogramming factors in iPSCs151 and thus, the differences we see in OSKM content reflect a 
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bias for particular combinations selected for in late reprogramming events (ie. TRA-1-60+ cells) and do 
not result preferential inactivation of any one factor.  
By examining the trajectories followed by cells reprogrammed with either Mono or Poly viruses, 
we notice that cells from the Mono condition exhibit a delay in the activation of several pluripotency loci 
including POU5F1, NANOG, DNMT3B and LIN28 compared with Poly reprogramming. We also 
observe a similar delay in the activation of these same loci in MRC-5 versus BJ fibroblasts. The period 
preceding the activation of the core pluripotency circuitry is referred to as latency, which is thought to be 
a major rate-limiting step in generating iPSCs. Our observation that latency is increased in the two 
conditions with relatively lower efficiencies (Mono and MRC-5) lends support to this notion and to our 
knowledge, is the first time this phenomenon has been measured between distinct conditions. It is 
commonly believed that latency results from the remodeling of the epigenetic landscape to allow the 
activation of pluripotency loci and it is expected that different factor stoichiometries or starting cell types 
would affect the rate at which this occurs5,50,66,101,125,158. If true, this would imply BJ cells have a more 
permissive chromatin state at some loci than MRC-5 fibroblasts, facilitating their activation. A rigorous 
comparison of reprogramming in cell types with divergent chromatin states would directly address this 
hypothesis and represents an important future direction of this work.  
Despite the differences observed early in the process, cells from all conditions activate 
pluripotency genes in a similar probabilistic order following the period of latency, suggesting a common 
mechanism in establishing pluripotency. The convergence on a common trajectory late in the process 
resembles the deterministic phase described by Buganim et al, however in our system these gene 
activation events are independent and probabilistic and thus we don’t believe that our observation 
represents a strictly deterministic process.  It is also somewhat surprising that different reprogramming 
conditions result in similar reprogramming trajectories given the variation in quality and differentiation 
potential of iPSCs derived from these different methods31,159. This implies that variation in iPSC 
phenotype results not from differences in how the pluripotency network is established but is likely due to 
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differences not analyzed in our study. This could result from differential expression genes whose 
expression alter iPSC phenotype, or could occur at the epigenetic level, as has been shown for the Dio-
Dlk3 locus in mouse101. 
In contrast to the similarities between BJ and MRC-5 at the transcript level, the surface markers 
SSEA4 and TRA-1-60 label slightly different populations between cell types. While the reason for this is 
unclear, it illustrates the impact of cell type on selecting informative biomarkers to isolate cells from 
different parts of the reprogramming process. SSEA4 and TRA-1-60 are also unique in that they are the 
only markers examined in our study that exhibit a strict order of activation; SSEA4 turns on before TRA-
1-60 and all TRA-1-60+ cells are also SSEA4+. This is very different from the probabilistic order 
observed at the transcript level for the majority of genes in our panel and it begs the question as to 
whether the process is more highly ordered or deterministic at the level of protein expression. Recently 
several groups have begun to explore the dynamics of the proteome during reprogramming, however this 
has not yet been coupled with transcriptional analysis and all studies to date have been performed in 
mouse. Indeed, this remains an important area of study in the field of reprogramming.  
Taken together, our study demonstrates that different reprogramming paradigms have the greatest 
effect early in the process during the period of variable latency. Once pluripotency gene expression is 
initiated, cells from all conditions follow a similar path to the pluripotent state as long as OSKM 
expression is maintained. The establishment and maintenance of factor expression is a critical challenge 
in monocistronic reprogramming as not all cells receive the full OSKM cocktail, nor do they maintain 
their expression throughout the process in all cells. This is a key advantage of the polycistronic method 
which ensures delivery of all four factors on a single construct. Our ability to make these conclusions 
relies on the single-cell resolution of our analysis and the comparison between multiple reprogramming 
conditions and demonstrates the need for rigorous comparison between protocols in order to determine 
the effect of procedural variables on the reprogramming process.  
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Chapter 4 Protein-Level Analysis of Human Reprogramming 
4.1 Introduction 
Reprogramming of adult somatic cells to a pluripotent embryonic-like state can be achieved 
through overexpression of the four Yamanaka factors OCT4, SOX2, KLF4 and c-MYC and has been 
successfully performed in both human and mouse 2,160. The development of human reprogramming in 
particular represents a promising means to obtain patient-matched stem cells for therapeutic purposes and 
for the modeling of disease states where the cells of interest are not readily accessible such as 
Alzheimer’s and Parkinson’s disease. The great potential of this technique is limited however, by the low 
efficiency of the process as well as the variability in the quality and differentiation potential of the 
resulting iPSCs46,118,119. This has spurred a flurry of research in recent years to define the molecular 
changes occurring as cells acquire a pluripotent phenotype with the goal of increasing the efficiency and 
reproducibility of the process.   
 Many efforts to understand the reprogramming process have focused on transcriptional dynamics 
both in bulk samples as well as in single cells 9,38,56,149. This work from our group and others has resulted 
in a two phase model of reprogramming whereby the expression of transcripts early in the process is 
loosely ordered and probabilistic, with genes behaving independently of one another. Late in the process 
mRNA expression shows increased dependency and coordination, characteristic of a gene regulatory 
network (GRN) that stabilizes cells in the pluripotent state. It is thought that the early probabilistic 
expression of mRNAs is a rate-limiting step in reprogramming as this phase is protracted and only a 
minority of cells progress past this point in the process. In addition, compounds that increase the rate and 
efficiency of reprogramming result in greater coordination between transcripts, suggesting a more rapid 
and robust activation of the pluripotency GRN facilitates reprogramming161.  
 The independent behavior of transcripts during the probabilistic phase of reprogramming is often 
attributed to locus-specific epigenetic barriers that prevent the activation of individual loci despite the 
expression of other members of the GRN and indeed, the rate limiting effects of the epigenetic landscape 
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on reprogramming are well established7,9,63,65,68. However, the expression of members of the pluripotent 
GRN is largely based on mRNA expression analysis and it is unclear whether these transcripts are 
translated into protein, which is requisite to exert their function. At the time this project was initiated, 
very little was known about protein expression during the course of reprogramming. Reprogramming 
systems in mouse utilizing GFP reporters for Nanog and Oct4 demonstrated that expression of these 
proteins is a late event in the process, however detection of these mRNAs occurs as early as Day 4 of 
reprogramming50,51,113,149,162. In addition, we and others had observed that two surface markers commonly 
used to enrich for reprogramming intermediates, SSEA-4 and TRA-1-60 are expressed in a dependent 
manner (i.e. SSEA-4 is always activated before TRA-1-60). This raised the question of whether protein 
expression is delayed compared with mRNA expression and if once expressed, proteins exhibit more 
coordinated and dependent behavior than their cognate transcripts.  
 In the year since this project began, three groups have performed protein expression analysis on 
mouse cells during reprogramming58,59. Zunder et. al. used mass cytometry to examine the expression of 
37 proteins in secondary reprogramming mouse fibroblasts and were able to define a number of 
intermediate states of reprogramming that they present as evidence for reprogramming being more 
ordered at the protein level58,59. However, it is clear from their data that cells exist in a continuum between 
these states and no rigorous analysis of correlation or dependency between the proteins was performed.  
In addition, the mass cytometry data stands on its own and is not directly compared to the expression of 
the corresponding mRNAs.  In two separate studies, Benevento et. al. and Hansson et al. performed a 
more direct comparison of mRNA and protein using LC/MS-MS to profile the entire proteome in bulk 
reprogramming samples at different time points while collecting mRNA-seq data from the same 
experiment in parallel84,85. These data demonstrate that proteins involved in the same process or that exist 
is multi-subunit complexes are highly co-regulated while those involved in opposing processes exhibit an 
inverse expression pattern. Interestingly however, when these proteins are compared with their 
corresponding mRNA transcripts, they only exhibit strong correlations early in the process, with a greater 
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discordance between the two late in reprogramming. Taken together, these studies provide strong 
evidence that post-transcriptional mechanisms exist as cells approach pluripotency and may indeed be a 
key step for generating iPSCs.  
 Because these data were generated in the mouse system and in bulk samples, it remains unclear 
how these data translate to human reprogramming and whether these observations apply to the minority 
of cells undergoing productive reprogramming. To this end, we utilized CyTOF technology to profile the 
expression of 37 proteins at time points throughout the reprogramming process and compared these 
results with our previously generate single-cell mRNA expression data. Here we directly compare the 
reprogramming trajectories of cells at the mRNA and protein level and identify genes putatively subjected 
to post-transcriptional regulation. Additionally, we construct mathematical models to assess the degree of 
dependency between mRNAs and proteins and provide evidence for tighter regulation at the protein level. 
This dataset, while limited in scope, suggests translation of stochastic transcripts into protein may also be 
rate limiting in human reprogramming and that in general, the reprogramming process is more ordered at 
the protein level. This work lays the foundation for a more extensive study of mRNA and protein 
expression dynamics in single human cells during reprogramming in future work.  
4.2 Results 
4.2.1 Experimental Design 
To profile the dynamics of protein expression during reprogramming, BJ fibroblasts were 
infected with polycistronic lentivirus containing the OSKM reprogramming factors. Cells were harvested 
at days 4, 7, 11, 14 and 21, the same time points used in our previous mRNA analysis. We also collected 
BJ fibroblasts and H9 hESCs to represent the beginning and end points of the process, respectively. 
Following harvest, cells were stained with metal-labeled antibodies, barcoded and run in parallel on the 
Helios™ CyTOF instrument to measure the expression of 27 proteins in ~1 million individual cells. 
Barcoding allows different samples to be combined into a single staining reaction and run simultaneously 
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on the CyTOF to minimize technical variation (Figure 16). These samples are then computationally de-
multiplexed after acquisition using the manufacturer’s software. The proteins analyzed were chosen from 
our 96-gene mRNA expression panel where antibodies were available (Supplemental Table 7). Preference 
was given to antibodies previously validated for use in flow cytometry to simplify their optimization for 
CyTOF. Antibodies were further validated and titrated on BJ fibroblasts and H9 hESCs to confirm their 
specificity and expression in the appropriate cell type. This resulted in 13 targets that could be directly 
compared to the mRNA dataset. Additional targets were chosen based on the work of Zunder et al.58,59 
and include the intermediate markers CD73, CD49d, CD200 and PDGFRa, as well as EpCAM, an 
epithelial marker expressed in hESCs. 
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4.2.2 Defining the Productive vs Alternate Reprogramming Trajectories 
In order to model the expression of proteins during reprogramming it is essential to profile only 
the cells undergoing productive reprogramming, as unproductive events will likely exhibit different 
behavior and will confound the analysis. To determine which cells were productively reprogramming we 
used the viSNE algorithm to project our data into 2 dimensions, while conserving the relationships 
between cells in the original high-dimensional dataset163 (Figure 17A). Importantly, viSNE is intended for 
use with non-linear data, particularly flow cytometry data, making it ideal for this application. 
Examination of the viSNE projection shows a clear separation of the fibroblast and hESC groups, with a 
wide range of reprogramming cells spanning these two populations. This reprogramming population is 
rapidly distinguished from the fibroblast group as early as day 4, and progresses toward a hESC-like 
profile at subsequent days. 
The expression profiles of the reprogramming factors themselves distinguish cells that have 
received the virus from those that did not, since the antibodies recognize both the endogenous and 
exogenous proteins. Based on these results, there is a clear population of cells at the bottom of the graph 
that robustly express all four reprogramming factors (Figure 17B, red boxes). This is expected because 
the reprogramming factors are translated from a polycistronic mRNA and thus all cells that receive the 
virus should express the full complement of OSKM. In contrast, a population at the top of the map 
exhibits low or no expression of OSKM and is distinct from the fibroblast group, suggesting these are 
cells that received but pre-maturely inactivated the virus during the reprogramming process (Figure 17B, 
blue boxes). The low expression we detect in this group could reasonably be attributed to residual OSKM 
proteins that have yet to be turned over in the cell.  
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Having identified the productive population, we sought to measure the dynamics of gene 
expression as cells progress through the reprogramming process. Using the progression of cells over time 
as an approximation for reprogramming progress, we gated populations (Figure 18A) and measured the 
median expression of each protein in the panel. Unsupervised hierarchical clustering separates these gates 
into two major groups; an early group expressing fibroblast genes and lacking pluripotency gene 
expression and a late group with the inverse expression profile (Figure 18B). Within these broad 
classifications there is a progressive inactivation of the fibroblast genes LUM and LCK, and progressive 
activation of pluripotency genes such as EpCAM, DNMT3B and NANOG. Strikingly, several surface 
markers expressed in fibroblast cells are abruptly down-regulated between the early and late groups 
including CD13, CD44, CD49d and CD73. 
Because the above analysis relies on temporal changes in the data, which are known to be 
asynchronous between cells, we turned to a recently developed, unsupervised algorithm wanderlust, 
which was developed to identify cell-state transitions from high dimensional CyTOF datasets164. Briefly, 
wanderlust uses a graph-based approach to construct a k nearest neighbor graph of all the cells in the 
dataset, based on their similarity (in this case, protein expression profiles). The algorithm then computes 
the shortest distance from each cell to a pre-defined starting cell population (fibroblast) and a randomly 
chosen waypoint cell, using nearest neighbors as steps along the path. The cells are then ordered based on 
these distance measurements. This process is repeated iteratively using a randomized subset of k-nearest 
neighbors until convergence, providing a robust trajectory measurement. The utility of this approach is 
clear when the wanderlust trajectory is mapped onto our viSNE graph (Figure 18A). This trajectory 
meanders through the viSNE space, ordering cells based on protein expression similarity in a way that 
could not be achieved through manual gating and provides a continuous measure of reprogramming 
progress.   
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Measuring protein expression dynamics along the wanderlust trajectory reveals two key 
differences between the productive and non-productive trajectories. First, the non-productive population 
exhibits low expression of the proliferation marker Ki67, a marker that is progressively upregulated in the 
productive reprogramming populations as cells approach the hESC state (Figure 18D, right panel). This 
finding is in line with data from Zunder et. al. in mouse that identified a Ki67-null population that had 
exited the cell cycle and when enriched by FACS and cultured for several days, failed to produce iPSC 
colonies. Second, the non-productive population robustly expresses PDGFRa, a marker that is absent in 
fibroblasts cells but activated early in the productive trajectory (Figure 18D, left panel). PDGFRa is 
eventually downregulated in the productive cells as they approach the hESC state, indicating that the 
alternate group initiated, but will fail to complete reprogramming. Because PDGFRa is downregulated in 
the productive group late in the trajectory but remains expressed in the alternate group at all time points, it 
may be useful for negative selection against cells that are refractory to reprogramming at later stages of 
the process.  
Fibroblast and pluripotency genes exhibit the expected patterns of up- or down-regulation along 
the wanderlust trajectory but groups of genes appear to change in concert at particular points in the 
process (Figure 18 E and F). This is very different from the highly variable points of 
activation/inactivation observed from genes in our previous mRNA expression analysis and suggests 
potentially different expression dynamics at the mRNA and protein levels.  
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4.2.3 Delayed Protein Expression of Key Pluripotency Genes 
In order to directly compare mRNA and protein expression dynamics we first defined a common 
reprogramming trajectory between the two datasets, with the alternate trajectories removed. For the 
protein dataset, we examined only SSEA4+ events, since all cells collected for mRNA analysis were 
enriched for SSEA4 expression. We then used Euclidean distance to measure each cell’s similarity to both 
the fibroblast and hESC groups within a given dataset such that the mRNA reprogramming trajectory is 
relative to fibroblast and hESC mRNA profiles, while the protein trajectory is relative to the fibroblast 
and hESC protein expression profiles (Figure 19A and B).  It is clear that in both datasets there is a 
continuum of cell states between the fibroblast and hESC groups, although the protein dataset is slightly 
more diffuse in an orthogonal direction to the productive reprogramming axis.  
We next applied our Gaussian modeling pipeline to the two datasets to assess differences in the 
rate or timing of protein/mRNA expression. Because the protein expression dataset has nearly 1X105-fold 
more data points than the mRNA dataset, we down-sampled and bootstrapped the CyTOF data to reduce 
sampling bias. Comparing the model fits between the two datasets as a whole, we observe a slight 
tightening of the distributions in the protein dataset suggesting more rapid up- or down-regulation at the 
protein level, however this difference is not significant (α = 0.05) for all markers across the dataset 
(Figure 19C). A similar trend exists when comparing the mean point of activation/inactivation along the 
trajectory, where globally, there exists a slight delay in protein expression but again this difference is not 
significant (Figure 19D). When examining individual targets, it is clear that loci such as DNMT3B, 
NANOG and LUM have a significant delay in protein activation while other targets do not show an effect 
(Figure 19E and F).  
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4.2.4 Greater Co-Regulation of Protein than mRNA Expression 
To address whether protein expression exhibits greater co-regulation than mRNA expression, we 
measured the degree of correlation between markers within each of these datasets. First, we generated a 
background correlation that assumes independent behavior of all the genes. We then measured the 
Pearson correlations for all of the genes and subtracted the background to obtain our correlation-above-
background measurement. Figure 20 A and B demonstrates that when looking across all targets for each 
dataset, there is considerably greater correlation between proteins, compared with genes at the mRNA 
level. As expected, we observe strong correlation between the reprogramming factors, as these are co-
transcribed and co-translated from the polycistronic virus and the CyTOF antibodies recognize both the 
endogenous and exogenous species (Figure 20C). We also observe many strong correlations for 
increasing and decreasing loci in the protein dataset (Figure 20 D and E), much greater than what is 
observed when compared directly with correlations from mRNA expression data (Figure 20F).  
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4.3 Discussion 
Years of research on the molecular mechanisms of reprogramming have yielded valuable insights 
into key rate limiting steps but have been primarily focused on genomic analyses such as mRNA 
expression an epigenetic modifications. Until recently, the only studies of reprogramming at the protein 
level were limited to techniques such as immunohistochemistry, FACS or reporter constructs, which can 
only analyze a few markers at a time. The low throughput nature of these technologies limits their ability 
to identify novel protein biomarkers and to compare directly to the wealth of genomics data available. As 
a result, little is known about how proteins behave during reprogramming and whether post-
transcriptional mechanisms may be an additional rate-limiting step in the process.  
Here we present the first single cell protein expression analysis of reprogramming in human cells 
using CyTOF technology and directly compare these data with single-cell mRNA expression data. The 
single cell resolution of these datasets is essential for accurately comparing their dynamics during a 
highly heterogeneous and temporally asynchronous process and provides greater power to assess the co-
regulation of these molecules. The use of human cells is more directly relevant for therapeutic approaches 
and provides a necessary point of comparison for similar studies performed in mouse to determine the 
commonalities and differences between these two systems.  
A major finding of this work is that of the proteins examined, the pluripotency markers NANOG 
and DNMT3B are expressed significantly later in reprogramming than their mRNA transcripts. From our 
previous work we know that mRNA transcripts associated with pluripotency are expressed in a 
probabilistic fashion prior to being upregulated in the majority of cells by the end of the process, however 
it was unclear whether these transcripts were effectively translated into protein. The delayed expression of 
these markers at the protein level indicates their translation is a late event in reprogramming.  
81 
 
There are several reasons why this delay in translation might occur. One possibility is that the 
probabilistic expression of transcripts early in the process is ephemeral and does accumulate sufficient 
mRNA to be effectively translated, or that the amount translated is below the threshold of detection. This 
is unlikely to be the case however, as the expression levels of these transcripts is comparable to what is 
seen in hESCs, where expression of these genes as proteins is abundant. A more plausible explanation is 
the presence of miRNAs or other negative regulators of mRNA translation acting within the cell. Indeed 
many miRNAs are expressed in fibroblasts and the repression of aberrant transcripts is a common means 
of stabilizing cellular identity40,165–167, however it is unclear whether any of these target pluripotency 
genes. Analysis of miRNA expression during reprogramming has been reported previously42,152,168 and 
mining these datasets for miRNAs present in fibroblasts but downregulated in iPSCs coupled with a target 
prediction algorithm such as mirPath could identify putative regulators of this phenomenon. An 
alternative mechanism preventing the translation of probabilistically expressed mRNAs into protein is the 
absence of appropriate RNA binding proteins to stabilize the transcript or facilitate splicing into isoforms 
appropriate to the cell type. Indeed many stem-cell specific RNA binding proteins have been identified 
which presumably must be reactivated during reprogramming to achieve pluripotency169. The field of 
RNA biology is in its infancy however, and the role of cell-type specific RNA binding proteins is largely 
unknown.  
Regardless of the mechanism, delayed protein expression maybe be a rate limiting step in the 
process and manipulating regulators of this phenomenon could improve reprogramming efficiency. It is 
important to note that not all genes in our dataset follow this pattern and it is possible that the delay in 
protein expression may be the exception, rather than the rule in reprogramming. This has been 
demonstrated in proteomics analysis of mouse reprogramming where only a subset of genes, mainly those 
involved in cell adhesion and cell-to-cell signaling, exhibited poor correlation between mRNA and 
protein expression85. To determine how many targets exhibit this effect, a larger-scale analysis would 
need to be conducted. Indeed, a major limitation of the present study is the number of targets in the panel 
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that can be compared directly between the mRNA and protein datasets. When developing our panel for 
CyTOF, we started with a list of 96 genes for which we had already generated single-cell mRNA 
expression data. After selecting targets with reliable antibodies and validating on our own cell 
populations, we were left with 13 genes from the original panel. Additional markers of interest were 
chosen from the literature and brought the total number of proteins analyzed to 27, however these 
additional markers could not be compared with mRNA expression data. An important future direction of 
this work will be to perform single cell mRNA-seq analysis of the reprogramming process and to repeat 
the CyTOF experiment using a larger panel which is currently limited by the availability of rare metal 
conjugates to ~40 targets. This will provide a much larger dataset and allow for more confidence and 
robust statistical power to complement the data presented here.  
This work also demonstrates that greater coordination exists at the protein level when compared 
with the corresponding mRNA transcripts. This finding is somewhat expected given that not all 
transcripts are effectively translated into protein since the presence of the protein is typically required to 
exert function, for example regulating target genes. The increased correlation between proteins however 
does not directly imply that the process is more deterministic at the protein level. Simply visualizing the 
reprogramming trajectory derived from the protein expression data suggests a continuum of cell states 
rather than a series of discrete intermediates, however assessing the degree of deterministic behavior 
between proteins/mRNAs is a hypothesis that must be explicitly tested. A simple method of measuring 
determinism between genes is to compare the frequency with which one genes is activated before the 
other. A completely random system with no determinism between the genes would result in a frequency 
near 50%; an equal chance of either gene being activated, independently of the other. In a strictly 
deterministic situation, the probability of one gene activating before the other would be much greater and 
would approach 100%.  
Performing this test in a pairwise manner is straight forward, however looking at a complex 
system such as our reprogramming datasets, requires more sophisticated analyses. Bayesian analysis is a 
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powerful tool to estimate the probability of an event (expression of gene A) given other information about 
the system (expression of genes B, C, D etc.).  This analysis is particularly powerful when combined with 
single cell analysis because each single cell collected represents a measurement of the system, and the 
confidence of the predictions increases as more information is collected. Once all of the conditional 
probabilities of the system have been computed, a network diagram can be assembled to understand 
which genes are deeply integrated in the system and which are peripheral. It will be important to apply 
this method to both our mRNA and protein datasets to see if these networks are the same, and whether 
there is a difference in the dependence or connectivity of these systems. A caveat to this analysis is the 
need to reduce the continuous measurements obtained from the instrument, to a binary measure of 
presence or absence of expression. Single cell gene expression data lends itself well to this technique 
since cells with little/no expression lack detectable amounts of transcript and are thus have inherent zero 
values. In contrast, protein expression data from the CyTOF has no absolute zero values as even cells 
with no expression of a marker show some background staining. Several algorithms exist to binarize 
continuous datasets such as kmeans analysis or Euclidean distance stepping, both of which have been 
applied successfully to similar datasets such as microarray experiments. These analysis coupled with a 
larger mRNA and protein dataset for comparison will provide useful information about how effectively 
mRNAs are translated into protein during reprogramming and whether chemical or other interventions 
can overcome this hurdle. In addition, the analysis of a large protein dataset holds promise to identify new 
biomarkers of productive reprogramming that can be used to enrich or isolate cells with increased 
potential to become iPSCs. 
Chapter 5 Discussion and Future Directions 
5.1 Discussion 
The ability to reprogram somatic cells to pluripotent iPSCs was first demonstrated in 2006 and 
shows incredible promise as an autologous source of cells for transplantation and to model human 
diseases in vitro. The low efficiency of the process and heterogeneity of the resulting iPSCs however, has 
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limited the translation of this technique to a clinical setting. This led our group and many others to study 
the mechanisms governing the reprogramming process to identify rate-limiting factors and biomarkers of 
productive reprogramming.  
During the time this work was conducted the field of iPSC research progressed at a dizzying rate 
and many reports were published defining the molecular events preceding the acquisition of pluripotency. 
Many of these early studies profiled cell populations in bulk, but in recent years single cell analysis has 
been used to effectively describe the dynamics of reprogramming. Our group was the first to report single 
cell transcript analysis in human reprogramming and to our knowledge, are also the first to measure 
protein expression in human reprogramming as well. Through the measurement of 96 mRNAs and 27 
proteins (in separate studies) we mapped the progression of cells through the reprogramming process. 
Using mathematical models to describe the behavior of these molecules, we demonstrate that gene 
expression dynamics are ordered yet probabilistic, reconciling previous ordered and stochastic models of 
the reprogramming process. We also identify an alternate reprogramming trajectory of cells moving away 
from a fibroblast state but not towards pluripotency. Because cells on this trajectory fail to express many 
of the markers in our panel their exact molecular signature is unclear, however we confirm these cells are 
viable and lack detection of pro-apoptotic markers.  
We have also used our experimental pipeline to profile mRNA expression using different 
methods of reprogramming. At a time when many methods have been used to reprogram a variety of cell 
types, it is important to understand how and if variations in the technique impact the way in which cells 
achieve pluripotency. By comparing two delivery methods of the OSKM factors, we show that 
polycistronic reprogramming is more efficient than monocistronic reprogramming and that this is due at 
least in part to premature inactivation of the reprogramming factors in the monocistronic condition. This 
phenomenon also results in the alternate trajectory mentioned previously, which is present in the 
monocistronic but not polycistronic dataset. In a separate experiment reprogramming BJ and MRC-5 
fibroblasts with polycistronic virus, we find that the more efficient BJ cell type activates pluripotency 
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genes earlier in the trajectory however, the order of gene activation remains the same. This suggest a 
common reprogramming trajectory between these two cell types despite differences in efficiency.  
Outside the context of reprogramming, this body of work demonstrates the power of single cell 
analysis and mathematical modeling to dissect complex biological processes and gain insights not 
possible at the bulk-population level. Processes such as embryonic development and cell signaling exhibit 
temporal asynchrony and differential response between individual members of the population and are 
amenable to the methods presented here. By taking many molecular measurements (ie gene or protein 
expression) of each cell, we determine the relationship between cells, create a map of the process 
independent of time and determine a parsimonious trajectory along which to model the behavior of 
individual genes or proteins. This approach has since been applied by other groups164,170 and is quickly 
becoming a common tool for analyzing complex systems.  
5.2 Future Directions 
The findings presented here represent a first step in the analysis of human reprogramming at the 
single cell level and provide a framework to dissect the dynamics of the reprogramming process under 
different conditions. In this work, we employed the most common reprogramming methods to establish a 
“baseline” reprogramming trajectory in a relevant and widely applicable system. This same analysis 
however, can and should be expanded to a variety of reprogramming systems. One approach would be to 
determine the targets of small molecule compounds known to enhance the efficiency of the process. Many 
small molecules such as chromatin modifying compounds (TSA, VPA,5-Aza etc.), have known targets, 
while others such as OAC1, a compound identified in a screen for OCT4 activating agents, have no 
known mechanism of action71. A direct comparison of reprogramming with and without these molecules 
at the single cell level combined with our modeling technique is likely to reveal how these molecules 
enhance reprogramming efficiency and could help identify novel barriers to reprogramming. Importantly, 
single-cell mRNA-seq is quickly becoming a trivial technique and applying this technology to the 
86 
 
reprogramming paradigm avoids the barriers associated with selecting a panel with a limited number of 
targets.  
One important finding of this work is the independent behavior of individual loci during the 
stochastic phase of reprogramming, which suggests a local property of the gene governs its activity. In 
line with this conclusion, the epigenetic state of pluripotency loci is known to influence the order and 
timing of their activation. This implies that cell types with known differences in their epigenetic profiles 
should exhibit different gene expression dynamics during reprogramming, however this hypothesis has 
not been explicitly tested. We find a common reprogramming trajectory between BJ foreskin and MRC-5 
lung fibroblasts, however the similarity of their epigenetic profiles is unclear and little epigenetic 
profiling has been performed on MRC-5 cells. A more rigorous test of the hypothesis would be performed 
in many divergent cell types by single-cell mRNA-seq.  
The ENCODE project has performed ChIP-seq on dozens of commonly reprogrammed cell types, 
five of which were performed by the same lab and have perfectly overlapping datasets171. These cell types 
which include Human Skeletal Muscle Myoblasts (HSMM), Human Umbilical Vein Endothelial Cells 
(HUVEC), Human Mammary Epithelial Cells (HMEC), Normmal Human Epidermal Karatinocytes 
(NHEK) and Normal Human Lung Fibroblasts (NHLF) have been profiled for 12 different epigenetic 
modifications, many of which have established roles in reprogramming. These cell types and their 
accompanying epigenetic data represent a perfect system to assess whether variations in chromatin state 
impact reprogramming gene expression dynamics and whether this contributes to differences in efficiency 
between cell types. For example, cell types such as HSMM that have a largely repressive epigenetic 
environment may take longer to activate certain pluripotency loci and thus may reprogram at lower 
efficiency. In contrast, we would expect the opposite effect in HUVEC cells which have greater 
developmental plasticity and thus a more permissive epigenetic environment. These cell-type level effects 
would likely result from the facilitated or impaired activation of individual pluripotency loci in different 
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cell types. Identification of novel loci whose activation/repression impacts reprogramming efficiency 
would also be an important goal of future work.  
The protein expression analysis presented in Chapter 4 provides exciting preliminary findings that 
translation of stochastic transcripts into protein may be a rate limiting step in reprogramming and that the 
process as a whole may be better coordinated at the protein level. This analysis however relies on too few 
markers to definitively make this conclusion and several follow-up studies are necessary. First, a more 
comprehensive CyTOF experiment must be performed where there is greater overlap between the mRNA 
and protein expression datasets. This could be facilitated by mRNA-seq analysis of the reprogramming 
process to obtain data for the whole transcriptome. From this data a large panel of targets could be 
selected that are expressed/repressed at different points along the reprogramming trajectory. Starting with 
a large set of markers will ensure that a sufficient number of protein targets will remain after quality 
control and validation of the antibodies. With both the mRNA and protein data in hand, the degree of 
determinism in the system can be inferred by Bayesian methods and our modeling approach can be used 
to compare expression dynamics.  
Genes or proteins that appear dependent can also be validated by orthogonal experiments, such as 
those used by Buganim et. al. to validate their hierarchical model of the reprogramming process. This 
method uses single molecule Fluorescent In Situ Hybridization (smFISH) to label target mRNAs coupled 
with flow cytometry to measure the frequency with which one gene’s expression precedes another in 
thousands of individual cells. When coupled with antibody staining, this technique could also be used to 
visualize instances where the translation of an mRNA appears delayed, as observed for NANOG and 
DNMT3B in our existing dataset. Furthermore, smFISH can be combined with fluorescence microscopy 
to provide an absolute quantification of mRNA transcripts to determine whether translation of mRNAs 
into protein is subject to a threshold effect, or whether other post-transcriptional mechanisms are 
involved.  
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At a time when most reprogramming studies are performed in bulk populations of mouse cells, 
our profiling individual human cells undergoing reprogramming at the mRNA and protein levels 
represents an important contribution to the field. In addition, the mathematical modeling approach 
presented here can be used for future studies to interrogate the reprogramming process or other complex 
biological processes at the single cell level. Here we provide a powerful framework for similar analyses 
that will be required as the feasibility of, and necessity for, these experiments increase in the years to 
come.  
Chapter 6 Materials and Methods 
6.1 Production of Monocistronic OSKM Retrovirus 
Retroviral vectors (pMIG) containing OCT4, SOX2, KLF4, c-MYC (OSKM) along with helper 
plasmids (VSV-G and Gag-pol) were obtained from I.H.Park (Yale University, New Haven, CT). To 
generate viral particles, individual retroviral vectors were co-transfected with VSV-G and Gag-pol into 
293T cells seeded at 2 x 106 cells per 10-cm2 using FuGENE 6 transfection reagent (Roche Applied 
Science). After 72-hour induction, supernatants were collected, filtered through 0.45µm filter and 
concentrated using Vivaspin 300,000 MWCO PES filter columns (Sartorius). Viral titer was determined 
using FACS analysis for GFP expression (encoded in the pMIG vector). An MOI of 5 was used for all 
experiments.  
6.2 Production of Polycistronic OSKM Lentivirus 
Simultaneous delivery of the four reprogramming factors OCT4, SOX2,KLF4 and c-MYC was 
achieved using the STEMCCA-LoxP polycistronic lentiviral vector, a generous gift from Dr. Gustavo 
Mustolovsky (U. Mass Boston Medical School). Virus was produced by cotransfection of STEMCCA-
LoxP along with helper plasmids VSV-G, Gag-pol, Rev and TAT into 293T cells in 5 x 10cm2 dishes 
using Xtreme-GENE9 transfection reagent. 72hrs post-transfection, supernatant was harvested and 
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concentrated to 1mL using Vivaspin 300,000 MWCO PES filter columns (Sartorius), and 100ul of the 
concentrated virions were used for each reprogramming experiment.  
6.3 Construction of 3-Factor Reprogramming Lentiviruses 
The 3-factor polycistronic vectors were constructed by modifying STEMCCA-LoxP as follows. 
First, we removed either the OCT4-F2A-KLF4 or SOX2-E2A-cMYC cassette from the STEMCAA-LoxP 
vector using the NotI/BamHI and NdeI/BsaBI sites, respectively. The deleted cassettes were then replaced 
with one of the two original cDNAs to generate a 3-factor-containing polycistronic vector. The individual 
human cDNAs encoding the four reprogramming factors were amplified from the STEMCCA-LoxP 
vector using following primers: OCT4 NotI Poly F (5’-GCGGCCGCATGGCGGGACACCTGGCTTC-
3’); OCT4 BamHI Poly R (5’-GGATCCTCAGTTTGAATGCATGGGAGAG-3’); KLF4 NotI Poly F (5’-
GCGGCCGCATGGCTGTCAGCGACGCGCTG-3’); KLF4 BamHI Poly R (5’-
GGATCCTTAAAAATGCCTCTTCATGTG-3’); Sox2 NdeI Poly F (5’-
CATATGATGTACAACATGATGGAGACGG-3’); Sox2 BsaB1 Poly R (5’-
GATCCTAATCCTATGTGTGAGAGGGGCAGTGTG-3’); c-Myc NdeI Poly F (5’-
CATATGATGCCCCTCAACGTTAGCTTCACC-3’); c-Myc BsaB1 Poly R (5’-
GATCCTAATCTTACGCACAAGAGTTCCGTAGCTG-3’).  
  
6.4 Cell culture and Fibroblast Reprogramming 
MRC-5 human fetal lung fibroblasts were obtained from I.H. Park (Yale University, New haven, 
CT) at passage 8 and BJ human foreskin fibroblasts were purchased from Global Stem (GSC-3002) at 
passage 6. No cells beyond passage 10 were used for reprogramming. Briefly, fibroblast cells were 
expanded in human fibroblast (hFib) media (DMEM (Gibco), 10% FBS (Milipore), 1% L-glutamine 
(Gibco) and 1X Penn-Strep (Gibco)). One day prior to infection, 1 x 105 MRC-5 fibroblasts were seeded 
into one well of a 6-well dish containing hFib media. The next day, cells were incubated in RI media 
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(MEM alpha (Mediatech) and 10% FBS (Millipore)) containing 5ug/mL protamine sulfate (Sigma) and 
OSKM virions for 24hrs followed by replacement with fresh RI media. Cells were cultured for 72hrs 
post-infection and passaged to 10cm2 dishes pre-seeded with 7.5 x 105 inactivated feeders in hESC media 
supplemented with 10uM ROCK inhibitor (Y-27632, Calbiochem). Cells were split 1:2 for all 
monocistronic experiments and 1:3, 1:10, 1:20 and 1:30 for day 7, 11, 14 and 21 polycistronic 
reprogramming, respectively. After passaging, fresh hESC media was added daily until the end of the 
experiment. H9 human embryonic stem cells (WiCell) were maintained either on MEFs in hESC media 
(DMEM F-12 (Gibco), 20% Knockout-Serum Replacement (Gibco), 1% L-Glutamine (Gibco), 1% Non-
Essential Amino Acids (Gibco), 5µM β-mercaptoethanol (Gibco), and 2ng/mL b-FGF), or feeder-free on 
matrigel coated plates with mTesr-1 media following the manufacturer’s instructions. hESCs were 
passaged as single cells using hES Cloning Recovery Reagent (Stemgent) to enhance clonal survival.  
6.5 Antibody Staining and FACS Sorting of Reprogramming Cells 
Reprogramming fibroblast cells were harvested with 1mL Accumax (Millipore) per well (6-well 
dish) for 10 minutes at 37°C. Cells were pelleted, washed with PBS (Gibco) and wash buffer (2% FBS in 
HBSS (Invitrogen)), and resuspended in wash buffer. Cells were then stained for 30min using αSSEA-4 
(Biolegend, Cat# 330405) αTRA-1-60 (Biolegend, Cat# 330605) and αMEF (Miltenyi, 130-102-900) 
antibodies, washed 3 times and resuspended in FACS buffer (1% FBS in PBS). For FACS, cells were 
live/dead stained and gated on GFP (for monocistronic reprogramming) and appropriate surface markers 
as indicated and single cells sorted into 96 well PCR plates. All FACS was performed using a BD 
Bioscience FACS Aria II. 
6.6 AP Staining and Surface Marker Quantification 
Alkaline phosphatase staining was performed in 6-well plates using the alkaline phosphatase 
detection kit (Millipore) per the manufacturer's instructions. Plates were images in bright field on an 
Olympus SZ61 dissecting microscope and colony number and total area were counted using ImageJ.  To 
accurately quantify the percentage of SSEA4+ and TRA-1-60+ cells from each condition,  we stained 
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with biotinylated α-SSEA4 (Biolegend, 330404) or α-TRA-1-60 (Biolegend,330604) primary, followed 
by Brilliant Violet-421 secondary (Biolegend 405226) and APC α-MEF (Miltenyi) at reprogramming day 
14 and 21. All experiments above were performed in biological triplicate. 
6.7 Quality Control and Single Cell qRT-PCR 
Single cell qRT-PCR was performed as previously described 126. Single cells were sorted by 
FACS into lysis solution (5% NP-40, 1000U RNasin plus (Promega, PRN2615)) and denatured by 
incubating at 70°C for 10 minutes and then cooled to 4°C. Cells were then reverse transcribed with 
MMLV (Promega, PR-M1705) and pre-amplified with TAKARA PCR Master Mix (TAKR004A) using 
gene specific primers (0.25X pooled TaqMan assays). qPCR was performed either using TaqMan 
chemistry in 384 well plates on an ABI 7900HT Fast Real-Time system, or in 96.96 Dynamic Arrays on 
the BioMark-HD® system (Fluidigm). Average cycle threshold (Ct) values obtained from qPCR reactions 
were normalized to GAPDH (∆Ct), and inverted by taking the (40 – ∆Ct) value. To reduce technical error 
and ensure robust sample quality, all cells with a GAPDH Ct value of 25 or greater were excluded from 
further analysis. TaqMan assays for endogenous OCT4, SOX2, KLF4 and c-MYC were directed against 
the 3’-UTR region of the transcript, which is distinct from the synthetic UTRs incorporated in the 
monocistronic OSKM transgenes, conferring their specificity to the endogenous transcripts. To test for 
the presence of the viral transgenes in monocistronic reprogramming, primers targeting the synthetic 
O,S,K and M UTRs were used for RT, Pre-Amp and analysis by SYBR green qPCR on an ABI 7900HT. 
These primers are listed in (Supp) 
6.8 Marker Panel Selection 
Genes selected for inclusion in our 96 marker panel were chosen based on several criteria. For 
pluripotency and chromatin modifier genes we selected those whose role in the establishment or 
maintenance of the pluripotent state was well documented and experimentally validated. This decision 
was further informed using the dataset of Dowell et. al. 172 which assigns a self-renewal score to genes 
based on their integration in the pluripotency gene regulatory network (as determined by direct binding of 
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O, S, K and/or M) as well as their degree of co-expression with well-established pluripotency genes. 
Fibroblast genes were selected based on their expression in fibroblasts and absence from hESCs as 
determined in 128,173. 
6.9 Data Analysis from Chapter 2 
6.9.1 Mapping the Reprogramming Trajectory 
The Euclidean reprogramming trajectory was determined by reducing gene expression to 
0(undetected) and 1(detected, Ct < 40) and calculating the average Euclidean distance for each cell to the 
FIB and PLURI groups, ignoring self-comparisons. Similarity was computed for each group distance by 
taking the ratio of the distance between FIB and PLURI minus each cell’s distance to the group in 
question, over the distance between FIB and PLURI minus the average distance of that group to itself. 
The average of the similarity to PLURI and the complement of the similarity to FIB was taken as an 
estimate of the progression of each cell along the reprogramming trajectory. Distance off of the trajectory 
was taken as the Euclidean distance from the FIB and PLURI similarities to the trajectory value. 
6.9.2 Self-Organizing Map Analysis 
PCA-based SOM analysis was performed in JMP, Version 10 (a SAS product)174 using a 5-by-1 
matrix and visualizing on a biplot (PC1 vs PC2). Cells within the “Alt” group were considered to be 
outliers (as described above) and were excluded from subsequent analysis, unless otherwise indicated.  
6.9.3 Hierarchical Clustering 
Hierarchical clustering was also performed in JMP, using Ward’s method with no 
standardization, on (40-∆CT) values. Coverage ellipses on the Euclidian distance graphs represent 90% 
coverage of the data points from the group indicated. For correlation analysis Pearson’s correlation 
coefficients within a defined SOM grouping were taken for the entire 48x48 matrix of genes analyzed in 
this study. Network graphs were constructed in Cytoscape using a force-directed layout derived from the 
top 100 Pearson correlations between all of the cells, excluding outliers, in our analysis (n = 117). 
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6.9.4 Model Generation 
To generate accurate models, the data was first interpolated to generate a high resolution training 
set. The entire sample population was included, except for outliers considered as the cells with the highest 
distance off of the trajectory (10%, N=17). The training data represented the percentage of cells 
expressing a gene at any point along the PLURI trajectory, and was measured by uniformly placing 
overlapping bins of fixed width across the range and directly counting the number of cells expressing 
each gene. Models were generated to then predict the percentage expressing at any trajectory location. 
‘Uniform’ models were generated by assigning a ‘Baseline’ value at the start of the trajectory (=0), and 
fixing a slope such that a straight line passed from the ‘Baseline’ to the value at the end of the trajectory 
(=1). ‘Normal’ models were then fit to this data using the ‘optim’ function in R, attempting to minimize 
the mean squared error, using the constraint, 16/3≤StdDev  and the following form: 
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In order to verify model quality and compare fitting between different models, AICc was calculated and a 
bootstrapping test was performed. AICc was calculated by:  
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where n is the effective number of sample points present in the original data, k is the number of free 
model parameters, and MSE is the mean squared error from the model prediction to the training data. 
Bootstrapping was performed by repeatedly simulating the training data but using only n bins and 
randomly resampling a fixed number of cells from each bin’s range. The error between the model 
prediction and the resampled data was compared to the expected error using an F-test to predict if the 
error induced by lack-of-fit exceeded the pure error of the data by a significant level, and this was tracked 
as a percentage of all tests done against the model. 
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6.9.5 Correlation Analysis 
First, simulated populations of an equal size were generated by sampling a set of points along the 
reprogramming progression axis such that they matched the distribution of values in the original dataset. 
For each sampling point, representative of a single simulated cell, each gene was set to detected or 
undetected independently, using the frequency curves generated from our Gaussian model. Pearson 
correlation coefficients were then computed for this reference population, and averaged over repeated 
runs (n=1000000). Differences in correlation between this background dataset and those calculated for 
our observed data were then tested for significance using the ‘r.test’ function of the R package ‘psych’.  
6.10 Data Analysis and Modeling from Chapter 3 
qPCR data from the Biomark was binarized such that detected genes (Ct<35) and undetected 
genes were converted to 0 and 1 values, respectively. This dataset was then used for all subsequent 
analysis in R v3.0.1. We then developed a modeling pipeline to describe the expression changes occurring 
during reprogramming. First, we use PCA to reduce the data to two dimensions (PC1 and PC2) and we fit 
a polynomial regression curve to the data and define the reprogramming trajectory. We then project each 
cell to a point on the curve based on the shortest distance, providing a value for each call along the 
trajectory. The trajectory values are then scaled between 0 (fibroblast) and 1 (hESC) for easier 
interpretation. To model expression of each gene, we use the binary data and reprogramming trajectory to 
fit a logistic regression that describes the probability of detection as reprogramming progresses. 
Confidence intervals were created by bootstrapping the logistic fitting procedure 100 times and sampling 
with replacement to ensure robustness of the method.  
6.11 Cell Death Analysis 
To evaluate the degree of cell death due to inactivation of reprogramming factors, BJ fibroblast 
cells were reprogrammed using both polycistronic and 3-factor reprogramming vectors and cells were 
analyzed at day 14 and day 21 in triplicate. Cells were stained either with propidium iodide or α-cleaved 
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Caspase-3 (Cell Signaling, 9664P) to measure live/dead and apoptosis, respectively. All staining was 
performed at the manufacturer's recommended dilution and measured on a BD FACSCalibur instrument.  
6.12 Collection of Cells for CyTOF 
For CyTOF, we collected reprogramming cells at days 4, 7, 11, 14 and 21 as well as BJ 
fibroblasts and H9 hESCs. In order to minimize technical variation, reprogramming was initiated on 
different days and all time points were collected and processed in parallel.  On the day of collection cells 
were harvested with Accumax reagent and stained with IdU (Fluidigm, 201127) and Cisplatin (Fluidigm, 
201064) following the manufacturer’s protocol. A surface antibody cocktail was prepared by combining 
all surface markers in our panel in 100ul MaxPar Cell Staining Buffer (Fluidigm, 201068). 
Concentrations used for each antibody can be found in Supplemental Table 7.  3X106 cells from each time 
point were incubated in the antibody cocktail for 30min at 4C, then fixed and permeabilized using the 
MaxPar Nuclear Antigen Staining Buffer (Fluidigm, 201063) according to the manufacturer’s 
instructions. Cells were then barcoded using the Cell-ID 20-plex Pd Barcoding Kit (Fluidigm, 201060), 
combined into a single tube and stained with a cytoplasmic/nuclear antibody cocktail (100ul volume) 
following the Fluidigm Nuclear Antigen Staining Protocol. Nuclear staining and CyTOF data acquisition 
were performed by Fluidigm Sciences Inc (San Francisco, CA).   
6.13 Data Analysis for Chapter 4   
Visualization of the CyTOF dataset by viSNE and gating of cell populations was performed in 
Cytobank (www.cytobank.org). Hierarchical clustering, correlation analysis and modeling were 
performed as descried above with the exception that CyTOF dataset was downsampled to the same 
number and per-sample representation of cells and bootstrapped 100 times to avoid biases when 
comparing the two datasets. The results of the correlation analysis and model fits plot the average of these 
bootstrapped runs.  
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Chapter 7 Appendices 
6.14 Supplemental Figures 
6.14.1 Supplemental Figure 1 
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6.14.2 Supplemental Figure 2 
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6.14.3 Supplemental Figure 3 
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6.14.4 Supplemental Figure 4 
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6.14.5 Supplemental Figure 5 
 
108 
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6.14.9 Supplemental Figure 9 
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6.16 Authored Publications 
6.16.1 Single Cell Analysis Reveals the Stochastic Phase of Reprogramming 
to Pluripotency is an Ordered Probabilistic Process 
Chung, K.-M., Kolling, F. W., Gajdosik, M. D., Burger, S., Russell, A. C., Nelson, C. E. Single 
cell analysis reveals the stochastic phase of reprogramming to pluripotency is an ordered probabilistic 
process. PloS One, 9(4), e95304. (2014)  
Abstract: Despite years of research, the reprogramming of human somatic cells to pluripotency 
remains a slow, inefficient process, and a detailed mechanistic understanding of reprogramming remains 
elusive. Current models suggest reprogramming to pluripotency occurs in two-phases: a prolonged 
stochastic phase followed by a rapid deterministic phase. In this paradigm, the early stochastic phase is 
marked by the random and gradual expression of pluripotency genes and is thought to be a major rate-
limiting step in the successful generation of induced Pluripotent Stem Cells (iPSCs). Recent evidence 
suggests that the epigenetic landscape of the somatic cell is gradually reset during a period known as the 
stochastic phase, but it is known neither how this occurs nor what rate-limiting steps control progress 
through the stochastic phase. A precise understanding of gene expression dynamics in the stochastic 
phase is required in order to answer these questions. Moreover, a precise model of this complex process 
will enable the measurement and mechanistic dissection of treatments that enhance the rate or efficiency 
of reprogramming to pluripotency. Here we use single-cell transcript profiling, FACS and mathematical 
modeling to show that the stochastic phase is an ordered probabilistic process with independent gene-
specific dynamics. We also show that partially reprogrammed cells infected with OSKM follow two 
trajectories: a productive trajectory toward increasingly ESC-like expression profiles or an alternative 
trajectory leading away from both the fibroblast and ESC state. These two pathways are distinguished by 
the coordinated expression of a small group of chromatin modifiers in the productive trajectory, 
supporting the notion that chromatin remodeling is essential for successful reprogramming. These are the 
first results to show that the stochastic phase of reprogramming in human fibroblasts is an ordered, 
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probabilistic process with gene-specific dynamics and to provide a precise mathematical framework 
describing the dynamics of pluripotency gene expression during reprogramming by OSKM. 
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6.16.2 Development of intestinal organoids as tissue surrogates: Cell 
composition and the Epigenetic control of differentiation 
Cao, L., Kuratnik, A., Xu, W., Gibson, J. D., Kolling, F., Falcone, E. R., Ammar, M., Van Heyst, 
M.D., Wright, D.L., Nelson, C.E., Giardina, C. Development of intestinal organoids as tissue surrogates: 
Cell composition and the Epigenetic control of differentiation. Molecular Carcinogenesis, 202(April 
2013), 189–202. http://doi.org/10.1002/mc.22089 (2013) 
Abstract: Intestinal organoids are multicellular crypt-like structures that can be derived from 
adult intestinal stem cells (ISCs), embryonic stem cells (ESCs) or induced pluripotent stem cells (IPSCs). 
Here we show that intestinal organoids generated from mouse ESCs were enriched in ISCs and early 
progenitors. Treatment of these organoids with a γ-secretase inhibitor increased Math1 and decreased 
Hes1 expression, indicating Notch signaling regulates ISC differentiation in these organoids. Lgr5 and 
Tert positive ISCs constituted approximately 10% and 20% of the organoids. As found in native tissue, 
Lgr5 and Tert expressing cells resolved into two discreet populations, which were stable over time. 
Intestinal organoids derived from cancer-prone Apc(Min/+) mice showed similar numbers of ISCs, but 
had reduced Math1 expression, indicating a suppressed secretory cell differentiation potential (as found in 
intestinal tissue). Apc(Min/+) organoids were used to screen epigenetically active compounds for those 
that increased Math1 expression and organoid differentiation (including HDAC inhibitors, Sirtuin (SIRT) 
modulators and methyltransferase inhibitors). Broad-spectrum HDAC inhibitors increased both Math1 
and Muc2 expression, indicating an ability to promote the suppressed secretory cell differentiation 
pathway. Other epigenetic compounds had a diverse impact on cell differentiation, with a strong negative 
correlation between those that activated the secretory marker Muc2 and those that activated the absorptive 
cell marker Fabp2. These data show that ESC-derived intestinal organoids can be derived in large 
numbers, contain distinct ISC types and can be used to screen for agents that promote cell differentiation 
through different lineage pathways. 
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6.16.3 pH dependence of amylin fibrillization 
Jha, S., Snell, J. M., Sheftic, S. R., Patil, S. M., Daniels, S. B., Kolling, F. W., & Alexandrescu, 
A. T. pH dependence of amylin fibrillization. Biochemistry, 53(2), 300–10. 
http://doi.org/10.1021/bi401164k (2014) 
Abstract: In type 2 diabetics, the hormone amylin misfolds into amyloid plaques implicated in 
the destruction of the pancreatic β-cells that make insulin and amylin. The aggregative misfolding of 
amylin is pH-dependent, and exposure of the hormone to acidic and basic environments could be 
physiologically important. Amylin has two ionizable residues between pH 3 and 9: the α-amino group and 
His18. Our approach to measuring the pKa values for these sites has been to look at the pH dependence of 
fibrillization in amylin variants that have only one of the two groups. The α-amino group at the 
unstructured N-terminus of amylin has a pKa near 8.0, similar to the value in random coil models. By 
contrast, His18, which is involved in the intermolecular β-sheet structure of the fibrils, has a pKa that is 
lowered to 5.0 in the fibrils compared to the random coil value of 6.5. The lowered pKa of His18 is due to 
the hydrophobic environment of the residue, and electrostatic repulsion between positively charged His18 
residues on neighboring amylin molecules in the fibril. His18 acts as an electrostatic switch inhibiting 
fibrillization in its charged state. The presence of a charged side chain at position 18 also affects fibril 
morphology and lowers amylin cytotoxicity toward a MIN6 mouse model of pancreatic β-cells. In 
addition to the two expected pKa values, we detected an apparent pKa of ~4.0 for the amylin-derived 
peptide NAc-SNNFGAILSS-NH2, which has no titratable groups. This pKa is due to the pH-induced 
ionization of the dye thioflavin T. By using alternative methods to follow fibrillization such as the dye 
Nile Red or turbidimetry, we were able to distinguish between the titration of the dye and groups on the 
peptide. Large differences in reaction kinetics were observed between the different methods at acidic pH, 
because of charges on the ThT dye, which hinder fibril formation much like the charges on the protein. 
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6.16.4 SCLD: a Stem Cell Lineage Database for the annotation of cell types 
and developmental lineages 
Hemphill, E. E., Dharia, A. P., Lee, C., Jakuba, C. M., Gibson, J. D., Kolling, F. W., & Nelson, 
C. E. SCLD: a stem cell lineage database for the annotation of cell types and developmental lineages. 
Nucleic Acids Research, gkq941. (2010) 
Abstract: Stem cell biology has experienced explosive growth over the past decade as 
researchers attempt to generate therapeutically relevant cell types in the laboratory. Recapitulation of 
endogenous developmental trajectories is a dominant paradigm in the design of directed differentiation 
protocols, and attempts to guide stem cell differentiation are often based explicitly on knowledge of in 
vivo development. Therefore, when designing protocols, stem cell biologists rely heavily upon 
information including (i) cell type-specific gene expression profiles, (ii) anatomical and developmental 
relationships between cells and tissues and (iii) signals important for progression from progenitors to 
target cell types. Here, we present the Stem Cell Lineage Database (SCLD) (http://scld.mcb.uconn.edu) 
that aims to unify this information into a single resource where users can easily store and access 
information about cell type gene expression, cell lineage maps and stem cell differentiation protocols for 
both human and mouse stem cells and endogenous developmental lineages. By establishing the SCLD, 
we provide scientists with a centralized location to organize access and share data, dispute and resolve 
contentious relationships between cell types and within lineages, uncover discriminating cell type marker 
panels and design directed differentiation protocols. 
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6.16.5 Regulation of the Fanconi anemia pathway by a CUE ubiquitin-
binding domain in the FANCD2 protein 
Rego, M. A., Kolling, F. W., Vuono, E. A., Mauro, M., & Howlett, N. G. Regulation of the 
Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein. Blood, 120(10), 
2109–2117. (2012) 
Abstract: The Fanconi anemia (FA)-BRCA pathway is critical for the repair of DNA interstrand 
crosslinks (ICLs) and the maintenance of chromosome stability. A key step in FA-BRCA pathway 
activation is the covalent attachment of monoubiquitin to FANCD2 and FANCI. Monoubiquitinated 
FANCD2 and FANCI localize in chromatin-associated nuclear foci where they interact with several well-
characterized DNA repair proteins. Importantly, very little is known about the structure, function, and 
regulation of FANCD2. Herein, we describe the identification and characterization of a CUE (coupling of 
ubiquitin conjugation to endoplasmic reticulum degradation) ubiquitin-binding domain (UBD) in 
FANCD2, and demonstrate that the CUE domain mediates noncovalent binding to ubiquitin in vitro. We 
show that although mutation of the CUE domain destabilizes FANCD2, the protein remains competent 
for DNA damage-inducible monoubiquitination and phosphorylation. Importantly, we demonstrate that 
the CUE domain is required for interaction with FANCI, retention of monoubiquitinated FANCD2, and 
FANCI in chromatin, and for efficient ICL repair. Our results suggest a model by which 
heterodimerization of monoubiquitinated FANCD2 and FANCI in chromatin is mediated in part through 
a noncovalent interaction between the FANCD2 CUE domain and monoubiquitin covalently attached to 
FANCI, and that this interaction shields monoubiquitinated FANCD2 from polyubiquitination and 
proteasomal degradation. 
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6.16.6 The p21Cip1/Waf1 cyclin-dependent kinase inhibitor is required for 
the activation of the FA-BRCA pathway 
Rego, M. A., Mauro, M., Harney, J. A., Shen, M., Kolling, F. W., & Howlett, N. G. Abstract LB-
102: The p21Cip1/Waf1 cyclin-dependent kinase inhibitor is required for the activation of the FA-BRCA 
pathway. Cancer Research, 70(8 Supplement), LB–102. (2010) 
Abstract: Fanconi anemia (FA) is a rare disease characterized by congenital defects, progressive 
bone marrow failure and heightened cancer susceptibility. The FA proteins, BRCA1 and 
FANCD1/BRCA2 function cooperatively in the FA-BRCA pathway to repair damaged DNA. Activation 
of the FA-BRCA pathway occurs via the monoubiquitination of the FANCD2 and FANCI proteins, 
targeting these proteins to discrete nuclear foci where they function in DNA repair. The cellular 
regulation of FANCD2/I monoubiquitination, however, remains poorly understood. In this study, we have 
examined the roles of the p53 tumor suppressor protein, as well as its downstream target, the 
p21(Cip1/Waf1) cyclin-dependent kinase inhibitor, in the regulation of the activation of the FA-BRCA 
pathway. We demonstrate that, in contrast to p53, p21 has a major role in the regulation of the activation 
of the FA-BRCA pathway: p21 promotes S-phase and DNA damage-inducible FANCD2/I 
monoubiquitination and nuclear foci formation. Several lines of evidence establish that this effect is not a 
consequence of a defective G1-S checkpoint or altered cell-cycle progression in the absence of p21. 
Instead, we demonstrate that p21 is required for the transcriptional repression of the USP1 
deubiquitinating enzyme upon exposure to DNA-damaging agents. In the absence of p21, persistent USP1 
expression precludes the DNA damage-inducible accumulation of monoubiquitinated FANCD2 and 
FANCI. Consequently, p21(-/-) cells exhibit increased levels of mitomycin C-inducible complex 
chromosomal aberrations and elevated γH2AX nuclear foci formation. Our results demonstrate that p21 
has a critical role in the regulation of the activation of the FA-BRCA pathway and suggest a broader role 
for p21 in the orchestration of DNA repair processes following exposure to DNA crosslinking agents. 
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6.16.7 Functional interaction between the Fanconi Anemia D2 protein and 
proliferating cell nuclear antigen (PCNA) via a conserved putative 
PCNA interaction motif 
Howlett, N. G., Harney, J. A., Rego, M. A., Kolling, F. W., & Glover, T. W. (2009). Functional 
interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a 
conserved putative PCNA interaction motif. Journal of Biological Chemistry, 284(42), 28935–
28942. 
 
Abstract: Fanconi Anemia (FA) is a rare recessive disease characterized by congenital 
abnormalities, bone marrow failure, and cancer susceptibility. The FA proteins and the familial breast 
cancer susceptibility gene products, BRCA1 and FANCD1/BRCA2, function cooperatively in the FA-
BRCA pathway to repair damaged DNA and to prevent cellular transformation. Activation of this 
pathway occurs via the mono-ubiquitination of the FANCD2 protein, targeting it to nuclear foci where it 
co-localizes with FANCD1/BRCA2, RAD51, and PCNA. The regulation of the mono-ubiquitination of 
FANCD2, as well as its function in DNA repair remain poorly understood. In this study, we have further 
characterized the interaction between the FANCD2 and PCNA proteins. We have identified a highly 
conserved, putative FANCD2 PCNA interaction motif (PIP-box), and demonstrate that mutation of this 
motif disrupts FANCD2-PCNA binding and precludes the mono-ubiquitination of FANCD2. 
Consequently, the FANCD2 PIP-box mutant protein fails to correct the mitomycin C hypersensitivity of 
FA-D2 patient cells. Our results suggest that PCNA may function as a molecular platform to facilitate the 
mono-ubiquitination of FANCD2 and activation of the FA-BRCA pathway. 
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6.16.8 The Fanconi anemia protein interaction network: Casting a wide net 
Rego, M. A., Kolling, F. W., & Howlett, N. G. The Fanconi anemia protein interaction 
network: Casting a wide net. Mutation Research/Fundamental and Molecular Mechanisms of 
Mutagenesis, 668(1), 27–41. (2009) 
Abstract: It has long been hypothesized that a defect in the repair of damaged DNA is central to the 
etiology of Fanconi anemia (FA). Indeed, an increased sensitivity of FA patient-derived cells to the lethal 
effects of various forms of DNA damaging agents was described over three decades ago [A.J. Fornace, 
Jr., J.B. Little, R.R. Weichselbaum, DNA repair in a Fanconi's anemia fibroblast cell strain, Biochim. 
Biophys. Acta 561 (1979) 99-109; Y. Fujiwara, M. Tatsumi, Repair of mitomycin C damage to DNA in 
mammalian cells and its impairment in Fanconi's anemia cells, Biochem. Biophys. Res. Commun. 66 
(1975) 592-598; A.J. Rainbow, M. Howes, Defective repair of ultraviolet- and gamma-ray-damaged DNA 
in Fanconi's anaemia, Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 31 (1977) 191-195]. 
Furthermore, the cytological hallmark of FA, the DNA crosslink-induced radial chromosome formation, 
exemplifies an innate impairment in the repair of these particularly cytotoxic DNA lesions [A.D. 
Auerbach, Fanconi anemia diagnosis and the diepoxybutane (DEB) test, Exp. Hematol. 21 (1993) 731-
733]. Precisely defining the collective role of the FA proteins in DNA repair, however, continues to be 
one of the most enigmatic and challenging questions in the FA field. The first six identified FA proteins 
(A, C, E, F, G, and D2) harbored no recognizable enzymatic features, precluding association with a 
specific metabolic process. Consequently, our knowledge of the role of the FA proteins in the DNA 
damage response has been gleaned primarily through biochemical association studies with non-FA 
proteins. Here, we provide a chronological discourse of the major FA protein interaction network 
discoveries, with particular emphasis on the DNA damage response, that have defined our current 
understanding of the molecular basis of FA. 
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6.17 Manuscript Under Review 
6.17.1 Comparison of Reprogramming Methods by Single Cell Analysis 
Identifies Premature Viral Inactivation as a Barrier to Successful 
Reprogramming and Reveals a Common Reprogramming Trajectory 
Between Cell Types 
Kolling, F. W., Chung, K.-M., Chen, K., Bar, H., Schifano, E. D., Harel, O., Mandiou, Ion I., 
Nelson, C. E. Comparison of Reprogramming Methods by Single Cell Analysis Identifies Premature 
Viral Inactivation as a Barrier to Successful Reprogramming and Reveals a Common Reprogramming 
Trajectory Between Cell Types. PloS One. (2015). 
Abstract: Reprogramming terminally differentiated cells to a pluripotent state by exogenous expression 
of the Yamanaka factors OCT4, SOX2, KLF4 and c-MYC (OSKM) has the potential to revolutionize 
many aspects of modern medicine. However, despite years of research this process remains highly 
inefficient and produces considerable cellular heterogeneity, problems that must be overcome before this 
technique can be used clinically. In the years following the first reports of OSKM-mediated 
reprogramming, several methods have been developed to reprogram cells to pluripotency in an effort to 
increase the efficiency and quality of iPSC generation, including using different methods of delivering the 
OSKM factors as well as the use of novel reprogramming factors. While many of these approaches have 
increased the efficiency and/or rate of reprogramming, at present it is unclear how these results manifest 
at the molecular level and how these various methods impact the quality and differentiation potential of 
resulting iPSCs. In this study, we apply single cell transcript analysis to compare the transcriptional 
dynamics underlying the acquisition of pluripotency in monocistronic and polycistronic OSKM systems. 
These two delivery methods were tested in both MRC-5 and BJ fibroblasts. We demonstrate that 
polycistronic viral delivery produces significantly higher reprogramming efficiencies compared with 
monocistronic delivery and that this effect is due in part to premature inactivation of the individual O,S,K 
or M vectors in the monocistronic method. In addition, we show that the activation of key pluripotency 
loci such as NANOG, OCT4, LIN28 and DNMT3B occurs earlier in the polycistronic condition and that 
these cells progress more uniformly towards pluripotency. Finally, we compare polycistronic 
reprogramming between MRC-5 and BJ fibroblast cells and reveal that while the order of gene activation 
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is similar between cell types; MRC-5 and BJ cells take divergent paths upon factor induction, followed by 
convergence later in the reprogramming process. 
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